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ABSTRACT 
Obesity is increasing worldwide in an epidemic manner and better prevention and treatments 
are urgently needed. Obesity is strongly associated with insulin resistance and predisposes for 
type 2 diabetes. A deeper understanding of the underlying mechanisms behind obesity-driven 
insulin resistance is needed to identify new potential treatment targets.  
Skeletal muscle is the main organ for glucose and fat metabolism. It is characterized by the 
ability to switch between glucose and fat as an energy source depending on the requirements 
and nutrient availability. This ability is referred to as metabolic flexibility. In the obese state, 
the skeletal muscle has a surplus of fatty acids and glucose, and this energy overload leads to 
stress and inflammation. This metabolic stress and inflammation, as well as the presence of 
excess fatty acids per se, impairs insulin signalling and metabolic flexibility in skeletal 
muscle. The overall aims of this thesis were to study the effects of energy alterations on gene 
expression, epigenetic marks, and lipid profile in blood and skeletal muscle to elucidate the 
underlying mechanisms leading to perturbations in skeletal muscle metabolism.  
The interplay between our genes and the environment to which we are exposed, can explain 
some of the obesity and insulin resistance epidemic. Different environmental factors may 
alter DNA methylation, which is an epigenetic modification that can alter the function of 
genes. In Paper I, we obtained peripheral blood from obese subjects before and after weight 
loss through a diet intervention and subsequent gastric bypass surgery. In the peripheral 
blood, we assessed the level of DNA promoter methylation on selected genes important for 
metabolism. Promoter DNA methylation of PGC1α was altered after diet-induced weight 
loss, while gastric bypass surgery, inducing a substantial weight loss, was associated with 
methylation changes of PDK4, TNF and IL6 promoters. In Paper II, we studied the effects of 
a short insulin exposure on skeletal muscle DNA methylation, and identified broad 
methylation changes in genes regulating metabolic pathways. One gene, previously not 
implicated in metabolic regulation, DAPK3, exhibited differential methylation status in 
response to insulin. DNA methylation of DAPK3 also differed between normal glucose 
tolerant and type 2 diabetic subjects, and changed in vivo in response to glucose ingestion.  
In Paper III we found that when skeletal muscle was exposed to AICAR, an activator of 
AMP-activated protein kinase, and a mimic of low cellular energy state, there was reduced 
expression of several cytokines, involved in metabolic inflammation. Using an unbiased 
bioinformatics approach, we identified the Sp1 transcription factor to be involved in the 
down-regulation of IL6 mRNA and the relatively unknown transcription factor Zbtb14 to 
alter LIF mRNA.  
In Paper IV, we again studied the effects of diet-induced weight loss in skeletal muscle of 
obese subjects. The three-week diet intervention reduced body weight and insulin levels. 
Gene expression of FATP1, MLYCD, PDK4, UCP3 and SCD1 was altered, all in favour to 
promote fatty acid oxidation in skeletal muscle. We also found an altered lipid profile, with 
specific lipid species associated with the improvement of skeletal muscle insulin sensitivity. 
In conclusion, we elucidate potential regulatory mechanisms of skeletal muscle metabolic 
health, which is of relevance in the overall understanding of the metabolic perturbations of 
obesity and insulin resistance. We show that DNA methylation is dynamic and a potential 
regulator of “immunometabolic” gene expression. We provide insight in how weight loss 
improves skeletal muscle metabolism and identify specific lipid species that may play a role 
in improving skeletal muscle insulin sensitivity.   
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1 INTRODUCTION 
 
1.1 Implications of obesity on world health 
Globally 1.9 billion adults are estimated to be overweight, which means that there are more 
people in the world who are overweight than undernourished (WHO, 2016b). In most 
countries worldwide, overweight and obesity kills more people than underweight. The 
worldwide prevalence of obesity in 2014 was estimated to 600 million individuals, a number 
that have more than doubled since 1980 (WHO, 2016b). Type 2 diabetes, ischemic heart 
disease and several types of cancer are strongly associated with obesity and cause premature 
morbidity and mortality, and constitute a major economic, medical and social burden in most 
countries. Recently, the World Health Organization (WHO) reported that 12.4 % of children 
under 5 years are overweight in the European region (WHO, 2016a), indicating that we have 
only seen the beginning of this epidemic. Despite this potential catastrophic scenario, it is 
important to keep in mind that obesity is preventable. The work of this thesis focuses on 
obesity and the associated insulin resistance, a metabolic state that precedes type 2 diabetes.  
 
1.2 Definitions and classifications 
Overweight and obesity are defined as an excess fat 
of weight in relation to height. Fat normally 
constitutes about 10-15 kg in middle-aged men, and 
about 50% more in middle-aged women (SBU, 
2002). The most commonly used measure of 
obesity is body mass index (BMI) (Table 1). BMI 
is calculated as kg of body weight per square meter 
of height (kg/m2).  
The different classifications of BMI reflect the 
associated risk of mortality and were developed by 
the WHO based on large epidemiological studies in 
North America (WHO, 1997). However, BMI does 
not discriminate between men and women and does 
not take into account the fact that the increased 
body weight can be due to increased skeletal muscle 
mass and not increased fat content.  
 
BMI, but also the localization of the adipose tissue, is associated with morbidity and 
mortality. When the adipose tissue is centred around the waist as in increased visceral, intra-
abdominal fat, the risk of developing cardiovascular disease as well as type 2 diabetes is 
increased to a higher extent (Despres, Lemieux, & Prud'homme, 2001). The waist-to-hip ratio 
is a measure that complements BMI, by taking into account the central, visceral fat. A person 
with a waist circumference of 102 and 88 cm for men and women respectively, is regarded as 
obesity (SBU, 2002).  
 
Table 1. Adult BMI classifications 
according to WHO (1997). 
BMI (kg/m2) Classification 
<18.5 Underweight 
18.5-24.9 Normal weight 
25-29.9 Overweight 
30-34.99 Obese class I 
35-39.99 Obese class II 
≥ 40 Obese class III 
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Other measures of fat mass include skin fold measurements and dual energy X-ray 
absorptiometry, as well as computer tomography (CT) and magnetic resonance imaging 
(MRI) scanning. MRI-scanning gives a very accurate readout of visceral and subcutaneous 
fat depots (Gray et al., 1991). However it is a very expensive technique that also requires the 
access to an MRI-scan, making it suitable exclusively for smaller research cohorts rather than 
population based measures. We have used BMI to describe our cohorts, as this is the most 
comparable means of measure in the literature.  
 
1.3 Mechanisms behind the development of obesity 
1.3.1 Energy homeostasis 
Obesity is a result of excessive energy intake or insufficient energy expenditure, or both 
(Figure 1). The energy content of food and drinks comes from fats, carbohydrates and 
proteins. Carbohydrates and protein contain less energy per unit than fat. Our body can 
regulate and limit the levels of carbohydrates and proteins stored in the body, but fat can be 
stored to a great extent. Energy expenditure includes basal metabolism, the thermic effect of 
food and physical activity. Easily accessible energy-dense food, in combination with reduced 
physical activity, is commonly accepted to be responsible for the fast development of obesity 
(WHO, 1997). 
Figure 1. Scale illustrates calorie intake/expenditure homeostasis. 
1.3.2 Genetics 
One idea that accounts for the current epidemic of obesity and type 2 diabetes centres around 
the “thrifty genes hypothesis”. The “thrifty genes hypothesis” suggests that certain genes, 
important for storing fuels as fat so that people can survive long periods of starvation, 
important historically in times of scares food availability. Now in modern time, in states of 
constant nutrient surplus, these genes important for storing fuel instead promote obesity, 
(Neel, 1962).  
Indeed our genetic heritage is important for the risk of developing obesity. Studies of twins 
have revealed that despite growing up in different environments, monozygotic twins still 
often share the same phenotype regarding body weight and BMI. Adoptive children also to a 
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large extent develop the same phenotype as their original parents, regardless of the food 
habits of the adoptive parents. (Stunkard, Foch, & Hrubec, 1986; Stunkard, Sorensen, et al., 
1986). Thus, there is a strong genetic component to body weight and BMI. 
More than 30 exceptionally rare monogenic obesity syndromes, including Prader-Willi 
syndrome, are identified as well as, 11 rare non-syndromic monogenic conditions related to 
obesity (Pigeyre, Yazdi, Kaur, & Meyre, 2016). One of the non-syndrome monogenic 
conditions is leptin deficiency (Zhang et al., 1994). Leptin is a protein that is released from 
adipose tissue that sends signals of satiety to the brain. Deficiency of the melanocortin-4 
receptor that relays the leptin signal in the central nervous system, is another monogentic 
obesity condition (Huszar et al., 1997). Thus, the deficiencies in the production or resistance 
to the action of secreted protein may also contribute to obesity.  
In addition, about 227 gene loci associated with the risk to develop obesity have currently 
been identified through genome wide association studies (reviewed in (Pigeyre et al., 2016)). 
One particular gene that has gained attention is the FTO gene (Frayling et al., 2007) and it has 
been shown that a person with one or two copies of the FTO allele have 1.2 or 3 kg extra 
weight respectively in comparison to a person who lacks the allele (Loos & Yeo, 2014). 
Although there is clear evidence that genes are important for the variation of body weight 
across a population, genetic variants only account for about 5% of the variation in body 
weight (Pigeyre et al., 2016) and thus cannot explain the pandemic of obesity. There are still 
missing links in the search for the aetiology of obesity. New research areas have emerged and 
gained focus the last centuries, such as the influence of our gut microbiota (Torres-Fuentes, 
Schellekens, Dinan, & Cryan, 2017), as well as the field of epigenetics (Kirchner, Osler, 
Krook, & Zierath, 2013), a regulatory mechanism investigated in this thesis. 
 
1.4 Epigenetic regulation 
The exact definition of epigenetics has been debated over the years. A definition commonly 
accepted is “the study of mitotically and/or meiotically heritable changes in gene function 
that cannot be explained by changes in the genetic sequence” (Riggs, 1996). The term 
“Epigenetics” was coined by the developmental biologist C.H. Waddington (1905-1975), in 
his classical description of the undefined cell type that rolls through the epigenetic landscape 
to become a highly defined, specialized cell (Waddington, 1957). “Epi” comes from the 
Greek prefix meaning “on top of”, which refers to a regulative mechanism “on top of the 
DNA sequence”. Epigenetic modifications of the genome include histone modifications, 
DNA methylation and microRNAs. These epigenetic marks influence the central dogma of 
DNA transcription, RNA translation and protein synthesis in the cell (Figure 2).  
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Figure 2. The “central dogma of biology”. DNA is transcribed to RNA, and RNA is 
translated to protein: Red arrows showing the points of interaction with the epigenetic 
regulatory mechanisms. Synthetic siRNA can be used experimentally to silence genes as 
described in the Methods section. 
DNA methylation of a promoter region of a gene often results in silencing and reduced 
mRNA transcription of that gene. Mechanistically, a methyl group (CH3) is attached to the 
5´carbon of the nucleotide side chain (Figure 3). This mechanism can modify the binding 
sites for the transcriptional complex and thus inhibit transcription. However, DNA 
methylation can also change the configuration of the DNA so that transcription is enhanced. 
Classically, a C nucleotide that precedes a G nucleotide in the DNA sequence is most 
commonly methylated, called CpGs. However, non-CpG methylation also exists, not only in 
plants where it was first discovered, but also in humans (Yan, Zierath, & Barres, 2011).  
 
Figure 3. The process of DNA methylation. A methyl (CH3) group is attached to the 5´carbon of 
the nucleotide side chain. 
DNA methylation is a well described regulatory mechanism in imprinting of genes, where 
during embryogenesis one allele of a gene is silenced to allow the other to be expressed (Reik 
& Walter, 2001). DNA methylation is also involved in oncogenic processes, where the genes 
involved in the repair mechanism of mutated genes are silenced through hyper-methylation, 
resulting in uncontrolled and heterogenic growth (Kulis & Esteller, 2010). DNA methylation 
may provide a potential molecular mechanism for the interaction between genetic and 
environmental factors also in metabolic homeostasis (Kirchner et al., 2013). David Barker 
was the first who recognized that nutritional status “in utero” could affect health later in life 
(Barker, 1990). Indeed, the children of mothers who experienced the Dutch famine while they 
were pregnant, had an altered DNA methylation of the insulin like growth factor 2 gene 
(Heijmans et al., 2008) and experienced greater risk of obesity and cardiovascular disease 
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later in life (Roseboom, Painter, van Abeelen, Veenendaal, & de Rooij, 2011). In the county 
of Överkalix in the north of Sweden, grandchildren of men that experienced scarce 
availability of food just before puberty, conversely exhibited increased longevity (Bygren, 
Kaati, & Edvinsson, 2001). Collectively, this indicates that epigenetic regulation is powerful 
in affecting lifetime and trans-generational risk for metabolic disease.  
Twin studies have shown that the blood epigenetic profile of 3-year old twins is very similar, 
but this profile changes substantially with age and exposure to environmental factors (Fraga 
et al., 2005). Exercise and weight loss through bariatric surgery are powerful external stimuli 
for epigenetic alterations (Barres et al., 2013; Barres et al., 2012). The epigenetic profile of 
skeletal muscle differs between people with type 2 diabetes and people with normal glucose 
tolerance (Barres et al., 2009), suggesting that epigenetic mechanisms can have a regulatory 
role also in the development of insulin resistance. Thus, changes in the epigenetic profile of 
type 2 diabetes, obesity and aging can be observed in blood, as well as metabolically active 
tissues such as skeletal muscle.  
 
1.5 Obesity and insulin resistance  
Obesity is responsible for driving the epidemic of insulin resistance and type 2 diabetes in the 
Western countries (Kahn, Hull, & Utzschneider, 2006). Insulin resistance is defined as the 
“inability to regulate glucose uptake in peripheral tissues” and is present in many metabolic 
diseases including type 2 diabetes, cardiovascular disease and hypertension (Reaven, 1988). 
Table 2. Definitions of impaired glucose tolerance and type 2 diabetes (WHO 2006). 
Classification Fasting plasma glucose  2-h plasma glucose 
Impaired fasting 
glucose 
6.1 to 6.9 mmol/L AND <7.8 mmol/L 
Impaired glucose 
tolerance 
<7.0 mmol/L AND ≥7.8 to <11.1 mmol/L  
Type 2 diabetes  ≥7.0 mmol/L OR ≥11.1 mmol/L 
In the clinical setting, there are two main diagnostic tests for type 2 diabetes: the fasting 
plasma glucose and plasma glucose measured 2 h after ingestion of a 75 g oral glucose drink, 
using an Oral Glucose Tolerance Test (OGTT) (Table 2). In addition, Haemoglobin A1c 
(HbA1c), a glycosylated form of haemoglobin, is also used as diagnostic criteria for type 2 
diabetes (≥6.5%) and reflects the long-term profile of blood glucose levels.   
Insulin resistance is rarely diagnosed in the clinical setting since clinical therapy guidance is 
based upon fasting blood glucose values, but can be measured by an euglycaemic clamp or 
estimated by the homeostatic model assessment (HOMA-IR) for research purposes. While 
HOMA-IR, calculated from the fasting glucose and fasting insulin values, mainly reflects the 
hepatic insulin resistance, the euglycaemic clamp is the “gold standard” method to assess 
insulin resistance, particularly in skeletal muscle (DeFronzo & Tripathy, 2009).  
Insulin is produced by the β-cells of the islets of Langerhans in the pancreas. The main task 
for insulin is to coordinate energy uptake and storage in the three main target organs skeletal 
muscle, liver and adipose tissue. Insulin inhibits energy generating processes like 
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gluconeogenesis in liver and lipolysis in adipose tissue. In the healthy individual, insulin is 
released by the pancreas after a meal and manages efficiently to clear the nutrients from the 
blood through a rapid uptake into the peripheral tissues. However, in the insulin resistant 
individual, peripheral tissues do not respond to insulin adequately and therefore glucose and 
fatty acid levels remain high in the blood. The pancreas responds with increasing the insulin 
production and secretion to maintain blood glucose levels within a healthy range. When the 
β-cells in the pancreas fail to meet the increased need for insulin, blood glucose levels rise 
and overt type 2 diabetes develops. Insulin sensitivity in the peripheral tissues can be 
improved by weight loss and exercise and thus type 2 diabetes can be prevented by lifestyle 
changes of the insulin resistant individual.  
1.5.1 Influence of ectopic fat 
Free fatty acids are taken up in response to insulin mainly by the adipose tissue, where they 
are primarily stored. However, when the adipose tissue is saturated as in obesity, fat can also 
be stored in liver and skeletal muscle, as ectopic lipids (Heilbronn, Smith, & Ravussin, 2004). 
Increased total lipid content in skeletal muscle is highly associated with obesity and insulin 
resistance (Krssak et al., 1999). However, with the finding that also highly insulin sensitive 
athletic individuals can have an increased total skeletal muscle lipid content, the general 
thought now is that the specific lipid species, as well as the localization, composition and 
turnover of lipids are more important for the development of insulin resistance (Coen & 
Goodpaster, 2012; Dube et al., 2008; Kitessa & Abeywardena, 2016).  
Fats/lipids do not only provide a source of energy, but also function as structural components 
in cell membranes. The phospholipid composition can affect the permeability and transport of 
nutrients across the cell membrane and alterations in the composition are associated with 
insulin sensitivity (Borkman et al., 1993). In addition, specific lipid species can also function 
as second messengers, and lipid intermediates such as ceramides and diacylglycerols are 
identified as inducers of insulin resistance in skeletal muscle (Hotamisligil et al., 1996; Yu et 
al., 2002). Thus, it is important to study the full lipid profile of the skeletal muscle to 
understand the underlying mechanisms connecting intramuscular lipids and insulin resistance.  
1.5.2 Influence of inflammation 
Type 2 diabetes and insulin resistance, with hallmarks like hyperglycaemia, hyperinsulinemia 
and elevated free fatty acid levels, cause tissue inflammation. The tissue inflammation per se, 
worsens the insulin resistance (Hotamisligil et al., 1996) causing a vicious circle. In people 
with type 2 diabetes, serum levels of acute-phase proteins (such as C-reactive protein, CRP), 
as well as cytokines (such as TNFα) are elevated (Spranger et al., 2003). Moreover, infusion 
of TNFα to healthy humans induces skeletal muscle insulin resistance (Plomgaard et al., 
2005). The tissue specific inflammation is however many times greater than the systemic 
(serum levels) response, suggesting that the tissues are directly affected locally in both an 
autocrine and paracrine manner (Osborn & Olefsky, 2012).  
In obesity, immune cells such as macrophages infiltrate adipose tissue (Weisberg et al., 
2003). Macrophages reside in adipose tissue depots and, through the release of chemokines 
and cytokines, they affect the surrounding insulin responsive tissues, rendering them insulin 
resistant (Lee & Lee, 2014; Olefsky & Glass, 2010). Additional evidence for the 
interconnection between metabolism and inflammation are the common signalling pathways 
(Figure 4).  
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Figure 4. Metabolic and inflammatory signalling pathways are interconnected through 
the JNK and IKK- pathways, that when activated, contribute to insulin resistance. 
Chronic low-grade inflammation stimulates the Jun N-terminal kinase (JNK) stress signalling 
pathway. In addition, elevated levels of free fatty acids, endoplasmic reticulum (ER) stress, as 
well as reactive oxygen species (ROS) generated from the mitochondria, can activate JNK 
(Ertunc & Hotamisligil, 2016). In obesity, JNK signalling is activated in liver, skeletal muscle 
and adipose tissues. Disruption of the JNK pathway prevents the development of insulin 
resistance and diabetes in obese mice (Hirosumi et al., 2002). Metabolic stressors like 
hyperglycaemia, hyperinsulinemia and elevated free fatty acid levels per se can activate 
inflammatory signalling pathways that lead to the activation of the transcription factor 
Nuclear factor κB (NFκB) (Yin, Yamamoto, & Gaynor, 1998). Disruption of this pathway 
can protect against the development of insulin resistance induced by high fat feeding in 
animal models (Yuan et al., 2001). Administration of anti-inflammatory salicylates blocks the 
NFκB signalling pathway and improves insulin sensitivity in humans (Shoelson, Lee, & 
Yuan, 2003). NFκB and AP-1 are the main transcription factors for many of the cytokines 
and therefore constitutes major convergent points for metabolic and immune signals. 
Collectively, inflammation is a cornerstone in metabolic perturbations and in the 
development of insulin resistance and type 2 diabetes. 
 
1.6 Skeletal muscle metabolism 
Skeletal muscle constitutes more than 40% of body mass and is unique when it comes to its 
ability to rapidly adapt to changing metabolic requirements. Skeletal muscle can increase its 
energy turnover by 100-fold during strenuous exercise in comparison to its resting state 
(Richter & Ruderman, 2009). Skeletal muscle is the major organ for insulin-stimulated 
glucose uptake and an important tissue for studying the mechanisms behind insulin 
resistance.  
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1.6.1 AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is the main fuel sensor in the cell coordinating the 
balance between ATP-consuming and ATP-producing pathways. Thus, AMPK is the key 
player in the regulation of body weight and whole body energy balance (Hardie, Hawley, & 
Scott, 2006). AMPK is activated by an increased AMP/ATP ratio and induces metabolic 
pathways that generates ATP and inhibits processes that require ATP (Figure 5).  
 
Figure 5. AMPK activates metabolic pathways resulting in ATP production 
(green arrows) and inhibits metabolic processes that require ATP (red lines). 
The activity of AMPK is decreased in adipose tissue of insulin-resistant obese individuals 
compared to obese individual who have normal glucose tolerance (Gauthier et al., 2011). 
Calorie restriction enhances insulin sensitivity (McCurdy & Cartee, 2005). Interestingly, in a 
study of mice lacking AMPKα2, calorie restriction did not enhance skeletal muscle insulin 
sensitivity compared to wild type mice (P. Wang et al., 2012), suggesting that AMPK plays a 
role in improving insulin sensitivity. Metformin, the first line oral treatment for type 2 
diabetes, is an AMPK activator. It also has anti-inflammatory effects (reviewed in (O'Neill & 
Hardie, 2013)), again connecting metabolic and inflammatory processes. In addition, other 
known AMPK-activators like salicylates and AICAR share these anti-inflammatory 
properties, of which the mechanisms are largely unknown. Thus, strategies to activate AMPK 
may prevent insulin resistance in metabolic diseases such as type 2 diabetes or obesity, with 
the inflammatory state is heightened. 
1.6.2 Mitochondria and metabolic flexibility 
Mitochondria are energy producing organelles in the cell that metabolize nutrients and 
produce ATP and are thus crucial for adequate energy production in skeletal muscle. 
Pyruvate from glycolysis, and fatty acids are transported to the mitochondrial matrix and 
oxidized to acetyl-CoA that enters the Krebs cycle where ATP is finally generated. 
Alterations in mitochondrial function have been implicated in the development of insulin 
resistance and obesity (Kelley, Goodpaster, Wing, & Simoneau, 1999; Kelley, He, 
Menshikova, & Ritov, 2002). 
The capacity of skeletal muscle “to utilize lipid and carbohydrate fuels and to transition 
between them” is defined as metabolic flexibility (Kelley et al., 1999; Kelley et al., 2002). 
Healthy skeletal muscle relies on lipid oxidation in times of fasting and during exercise, in 
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contrast, with insulin resistance, the fatty acid oxidative capacity of the mitochondria in 
skeletal muscle is impaired and fuel selection is shifted to glucose oxidation (Kelley et al., 
1999). One hypothesis of the association between mitochondrial dysfunction and insulin 
resistance involves fatty acid overload and incomplete lipid oxidation resulting in 
accumulation of intracellular lipid metabolites (J. Y. Kim, Hickner, Cortright, Dohm, & 
Houmard, 2000) that inhibit insulin signalling and subsequently impairs insulin-mediated 
glucose uptake (Yu et al., 2002). 
In this thesis, I focus on the expression of several genes involved in glucose and lipid 
metabolism that are of importance for mitochondrial function, fuel selection and implicated in 
the development of insulin resistance. Peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α) is activated by AMPK and stimulates mitochondrial function and 
thereby fuel disposal (Wu, Inskeep, Bowker-Kinley, Popov, & Harris, 1999; Z. Wu et al., 
1999). PGC-1α is down regulated in skeletal muscle from people with type 2 diabetes 
(Mootha et al., 2003). Another important mitochondrial enzyme is Pyruvate dehydrogenase 
kinase isozyme 4, mitochondrial (PDK4), located in the mitochondrial matrix and suppresses 
conversion of pyruvate to acetyl-coA, the rate-limiting step in glucose oxidation, favouring 
lipid oxidation. PDK4 in skeletal muscle is induced by exercise (Hildebrandt, Pilegaard, & 
Neufer, 2003), starvation and in people with type 2 diabetes (P. Wu et al., 1999). These two 
players are given high impact as main regulator switches for fuel selection in the 
mitochondria, essential for metabolic flexibility, making them potential targets for improving 
metabolic dysfunction and insulin resistance.  
1.6.3 Myokines 
Skeletal muscle, similarly to adipose tissue, produce and release cytokines to communicate 
the needs of the myocyte to other organs (Pedersen & Febbraio, 2008). These skeletal muscle 
specific cytokines are called “myokines” (Pedersen & Febbraio, 2008). Several internal and 
external stressors like exercise, and muscle contraction per se, inflammation, hyperthermia, 
ROS and low glycogen stores stimulate the production and release of myokines (Welc & 
Clanton, 2013). Currently, several hundred of myokines have been identified (Karstoft & 
Pedersen, 2016). The prototypic myokine is IL-6, which can be increased 100-folds in 
response to exercise (Keller et al., 2001), and is thought to be part of the anti-inflammatory 
and regenerative response of the muscle to exercise (Pedersen & Saltin, 2015). Cytokines 
seem to have different effects upon cell function depending upon the context in which they 
are produced, and also by what tissue and cell type. For example, when IL-6 is produced by 
the immune cells it induces inflammation and when it is produced by the muscle cell in 
response to acute exercise, it exerts anti-inflammatory effects (Pedersen & Febbraio, 2007). 
IL-6 is also important for whole-body metabolism. Deletion of Il-6 in mice leads to obesity 
(Wallenius et al., 2002). In contrast, gene delivery of IL-6 to mice fed a high fat diet induces 
weight loss and whole-body insulin sensitivity improvements (Ma, Gao, Sun, & Liu, 2015). 
This illustrates the complexity of IL-6 and underscores the importance of understanding how 
IL-6 is regulated and the effects on skeletal muscle and whole-body metabolism.  
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1.7 Interventions and treatments of obesity  
Obesity has been recognized as a threat to health since far back in history (Haslam, 2007). 
Galen, one of history´s greatest physicians gives one of the first descriptions of obesity 
management around 160A.D.;  
”I reduced a huge fat fellow to a moderate size in a short time, by making him run every 
morning until he fell into a profuse sweat; I then had him rubbed hard, and put into a warm 
bath; after which I ordered him a small breakfast, and sent him to the warm bath a second 
time. Some hours after, I permitted him to eat freely of food, which afforded but little 
nourishment; and lastly, set him to some work which he was accustomed to for the remaining 
part of the day”(Galen, AD 160) 
The first-hand treatment for obesity is lifestyle changes, including caloric restriction and 
increased energy expenditure. However, for successful weight loss through diet, there is a 
need for behavioural changes, as the aspect of food intake is highly associated with social 
habits and preferences.   
 
Figure 6. Recommended treatment of obesity. Redrawn from (SBU 2013). 
1.7.1 Weight loss through diet  
Caloric restriction is the first line of treatment for obesity in combination with other lifestyle 
changes (Figure 6). The daily caloric requirement to retain weight for a middle-aged (30-61 
years) person with average physical activity level is estimated to around 2,600 kcal for men 
and 2,100 kcal for women (Livsmedelsverket, 2017). The caloric requirements will, however, 
vary to a certain extent depending factors such as level of physical activity and skeletal 
muscle mass. A low calorie diet is defined as <1,000 kcal/day.  
Caloric restriction interventions can be successful to reduce weight in obese individuals, 
especially if combined with behavioural therapy. In the short-term (six months), a low 
carbohydrate diet has better weight loss effect than a low fat, diet but this difference is lost in 
the long term (1-2 years) (SBU, 2013). Weight loss through caloric restriction is efficient to 
improve insulin sensitivity (Lim et al., 2011). In addition, caloric restriction attenuates 
inflammation and intermittent fasting reduces serum cytokine levels in humans (Faris et al., 
2012; Heinonen et al., 2009), although there are some contradictory results that show that 
some cytokine levels are unaffected (Manco et al., 2007). Although caloric restriction can be 
successful, especially short term, most obese individuals fail to reduce their weight to normal 
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weight. Without substantial weight loss the risks of type 2 diabetes and cardiovascular 
disease remain. By studying caloric restriction and identifying the regulative mechanisms of 
improved metabolic health, it is possible to provide better dietary recommendations and 
prescribe treatment regimens. 
1.7.2 Pharmacological therapy 
Currently, three pharmacological treatments for weight loss are approved in Sweden today, 
the intestinal lipase inhibitor Orlistat, the anti-diabetic drug Saxenda (Liraglutid) and 
Mysimba (Naltrexone/Bupropion). Orlistat is a pancreatic lipase inhibitor that inhibits 
ingested lipids to be digested and taken up in the small intestine, jejunum and ileum, and the 
fats are instead excreted. Due to the side effects with diarrhoea and increased intestinal gas 
production many patients stop the treatment early. Saxenda is a GLP-1 (glucagon-like peptide 
1) receptor agonist. GLP-1 is a gut hormone released from the small intestine and involved in 
the regulation of appetite. Mysimba, is a combination drug of naltrexone, an opioid receptor 
antagonist, and bupropion, a dopamine- and norepinephrine-receptor inhibitor. Both Saxenda 
and Mysimba are not subsidized by the government in Sweden and are therefore very costly 
for the patients. The effect on weight loss is modest for all three drugs, a treatment lasting 
more than 52 weeks resulted in weight loss of 6.1%, 5.4% and 7.4% respectively compared to 
2.6%, 1.3% and 3% in the placebo group (Bray, Fruhbeck, Ryan, & Wilding, 2016). 
Nevertheless, given the world-wide increase in obesity, new treatment regimens are urgently 
required. 
1.7.3 Weight loss through bariatric surgery 
In the case of obesity and when weight loss through lifestyle changes and pharmacological 
treatment fails, there is an indication for bariatric surgery. The Swedish guidelines are 
adapted from NIH and prescribe surgery at BMI ≥40 or ≥35 with comorbidity (NIH, 1992). 
In 2016 about 6,000 patients underwent bariatric surgery in Sweden. The most common 
procedure is Roux-en-Y gastric bypass (RYGB) (64%) but Sleeve Gastrectomy (34%) 
continues to rise every year, both in Sweden and abroad (SOreg, 2017). In the RYGB 
procedure, the stomach is divided to create a smaller pouch, about 15-20 ml in volume 
(Figure 7).  
 
Figure 7. The current two main bariatric surgery 
techniques in Sweden. 
The small intestine, jejunum, is also divided and pulled up to make a gastrojejunal 
anastomosis. The major part of the stomach and the divided jejunum is anastomosed about 
1 m distal to the gastrojejunal anastomosis to enable for gastric and pancreatic juices to join 
with the ingested food. The method is both restrictive and malabsorptive, meaning that the 
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patient can only eat small portions of food, and fewer nutrients are absorbed due to the 
bypassing of the jejunum. Another important result of the gastric bypass is the change in 
gut hormone profile, including increasing GLP-1 (Falken, Hellstrom, Holst, & Naslund, 
2011). In the Sleeve gastrectomy procedure, the stomach is reduced into a “gastric sleeve” 
and the remaining part of the stomach is removed. Currently both procedures are performed 
by laparoscopy and the complications are few (SOreg, 2017).  
The prospective controlled Swedish Obese Subjects (SOS) Study has followed patients that 
underwent bariatric surgery 15-20 years ago. The study concludes that the maximum body 
weight loss occurs 1-2 years postoperatively (32±8%) and then stabilizes after 10-15 years 
(25±11%) (Sjostrom, 2008). The weight loss after bariatric surgery has prominent effects on 
blood glucose levels and after two years 72% of the diabetic patients improve in their blood 
glucose and insulin levels to the point that they can stop their diabetic therapy. After 10 years, 
the type 2 diabetes remission effect is retained for 36% of the patients (Sjostrom, 2008).  
RYGB surgery has substantial effects on insulin resistance, lowering blood glucose levels 
within days after surgery, before weight loss is significant. The mechanism behind this rapid 
amelioration is not completely stratified, but changes in gastrointestinal peptide release or the 
peri-surgical fasting itself could be involved (Falken et al., 2011; Lim et al., 2011; Thaler & 
Cummings, 2009). Cytokines levels are reduced independent of weight loss after RYGB 
(Miller, Nicklas, & Fernandez, 2011), suggesting that a reduction in inflammation could play 
a role in the early metabolic benefits after bariatric surgery. The fact that bariatric surgery is 
the only efficient, long lasting treatment for obesity, makes it an important model to study the 
mechanism of obesity and insulin resistance.  
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2 AIMS 
Obesity and insulin resistance are a consequence of a many known and unknown factors. The 
understanding of the underlying mechanisms leading to obesity and insulin resistance is 
crucial to identify persons at risk, being able to give better lifestyle intervention advice and to 
identify new approaches for medical treatment. Therefore, the overall aim of this thesis is to 
study the effects of external factors, such as low energy signals, weight loss, insulin and 
glucose exposure, on skeletal muscle and blood gene expression of healthy as well as obese 
and type 2 diabetic subjects. Ultimately, we aim to identify targets for improving skeletal 
muscle insulin sensitivity and metabolic health.  
The specific aims of this thesis are to; 
1. Determine if DNA methylation changes are present in human blood after a low calorie diet 
and after subsequent RYGB surgery. 
2. Investigate if insulin and glucose directly alter DNA methylation in skeletal muscle. 
3. Investigate the mechanism by which the AMP-mimicking AICAR reduces the mRNA 
expression of cytokines in skeletal muscle. 
4. Determine mRNA expression and lipid profiles of skeletal muscle in obese adults after 
short-term diet-induced weight loss. 
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3 EXPERIMENTAL PROCEDURES AND 
METHODOLOGICAL CONSIDERATIONS 
3.1 Human cohorts 
Five different human cohorts were included in this thesis. In paper 1, 18 (5 males and 13 
females) obese, non-diabetic subjects scheduled for RYGB surgery were enrolled. Whole 
blood was obtained to study clinical chemistry parameters and DNA methylation before and 
after a two-week low calorie diet. Whole blood from 7 of the subjects (1 male and 6 females) 
was also studied two days, and 12 months after RYGB surgery. A control group of 6 (6 
males) lean subjects undergoing elective cholecystectomy were also enrolled and their blood 
was obtained in the morning before, and one day after surgery.  
In papers 2, 3 and 4 skeletal muscle biopsies were obtained for DNA methylation, mRNA 
expression as well as protein analysis. Also samples for clinical chemistry was obtained at all 
time points. In paper 2, two different cohorts of male participants were studied. In the first, 
10 non-obese, normal glucose tolerant (NGT) subjects were enrolled for open muscle 
biopsies and clinical chemistry. In the second cohort, 12 normal glucose tolerant, as well as 
12 type 2 diabetic subjects were included. A conchotome muscle biopsy was taken before and 
after an oral glucose tolerance test (OGTT). In paper 3, 13 male, non-obese participants were 
enrolled for open muscle biopsy and blood chemistry. In paper 4, 8 (2 males and 6 females) 
obese, non-diabetic subjects were enrolled for conchotome muscle biopsies and clinical 
chemistry before and after a three-week low calorie diet. Written informed consent was 
obtained from all participants. The Ethics committee of Karolinska Institutet approved all 
studies included in this thesis. The clinical characteristics and clinical chemistry results of the 
cohorts are presented in Table 3. 
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  PAPER 1  PAPER 2 PAPER 3 PAPER 4 
Cohort   A B       
Metabolic state Obese Non-obese NGT NGT T2DM NGT Obese 
 
 
Before diet Op-day Discharge Follow-up Op-day Discharge         Before diet After diet 
N (Male/Female) 18 (5/13) 18 (5/13) 7 (1/6) 7 (1/6) 6 (6/0) 6 (6/0) 10 (10/0) 12 (12/0) 12 (12/0) 13 (13/0) 8 (2/6) 8 (2/6) 
Age (years) 40 ± 11 40 ± 11     33 ± 7 34 ± 6C 42 ± 9 42 ± 9 53 ± 6.3 60 ± 9.5 63 ± 3 50 ± 7.0 39 ± 12 39 ± 12 
Body weight (kg) 123.9 ± 15.9D 118.8 ±14.7A,D   81.0 ± 13.8A,B 82.2 ± 6.5   82.4 ± 8.5 80.8 ± 7.3 91.5 ± 6.3 80.2 ± 9.2 112. 9 104.9 ± 12.1* 
BMI (kg/m2) 42.3 ± 4.7D 40.5 ± 4.6A,D 
 
27.3 ± 3.3A,B 25.7 ± 2.1   25.2 ± 1.8 25.4 ± 1.6 28.3 ± 1.9* 24.0 ± 1.9 39.7 ± 3.5 36.9 ± 3.6* 
F- glucose (mmol/L) 5.7 ± 0.8 5.3 ± 0.9A 5.5 ± 0.9 4.7 ± 0.28A,D,E 5.3 ± 0.4 6.1 ± 0.5D 5.3 ± 0.3 7.4 ± 2.8 8.1 ± 1.3* 5.5 ± 0.3 5.7 ± 0.6 5.2 ± 0.3 
2-h glucose (mmol/L)   
    
    5.9 ± 0.9 15.8 ± 3.2* 
 
    
HbA1c (mmol/mol)       
  35.9 ± 1.9 37.1 ± 3.2 52.3 ± 7.3* 35 ± 2.5 35.9 ± 6.2  34.7 ± 4.2* 
F- insulin (mU/L) 27.0 ± 14.0D,E 19.8 ± 11.8D  22.2 ± 16.8 7.2 ± 2.18A,B,C,E 7.0 ± 2.0 11.6 ± 4.3D 5.3 ± 3.8 7.4 ± 2.8 14.5 ± 6.3* 7 ± 3.1 24.6 ± 9.3 10.7 ± 0.3* 
2-h insulin (mU/L)   
    
    42.3 ± 25.6 52.2 ± 26.6 
 
    
Triglycerides (mmol/L)   
    
  0.85 ± 0.3 0.98 ± 0.5 1.22 ± 0.5 1.1 ± 0.9 1.6 ± 0.5 1.1 ± 0.6* 
Tot cholesterol (mmol/L)   
    
  5.3 ± 0.9 5.1 ± 0.6 4.6 ± 0.6 5.9 ± 0.9 5.2 ± 0.7 3.8 ± 0.5* 
HDL cholesterol 
(mmol/L) 
  
    
  1.4 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 1.1 ± 0.2 
LDL cholesterol 
(mmol/L) 
  
    
  3.7 ± 0.6 3.4 ± 0.3 2.8 ± 0.9* 3.8 ± 0.6 3.2 ± 0.6 2.3 ± 0.6* 
HOMA-IRa 7.0 ± 4.1D,E 5.2 ± 4.5  5.9 ± 5.7 1.2 ± 0.68A,B,E 1.6 ± 0.5 3.2 ± 1.3D 1.2 ± 0.3 1.6 ± 0.6 5.4 ± 2.8* 1.8 ± 0.9 6.2 ± 2.5 2.5 ± 0.7* 
Table 3. Clinical characteristics. Data are presented as mean±SD. Paired and unpaired t-tests were used to test significance. α-level set at 0.05. *= significant in 
relation to NGT in paper 2 and in relation to before diet in paper 4. In paper 1, significance was marked as following; A=versus obese patients before diet, B= 
versus obese patients op-day, C= versus obese patients discharge, D=versus non-obese patients op-opday, E=versus non-obese patients discharge. Follow up time 
was 12.4±2.7 months from day of surgery. NGT=normal glucose tolerant, T2DM=Type 2 diabetes mellitus. 
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3.2 Skeletal muscle biopsies 
3.2.1 Open muscle biopsy 
In paper 3 and for the in vitro studies in paper 2, an open muscle biopsy technique was used 
to collect the muscle biopsies. The procedure has been previously described by our group 
(Zierath et al., 1992) and involves a larger biopsy with more intact skeletal muscle fibres 
compared to the more common muscle biopsy procedure. Presumably, the open muscle 
biopsy is also less “stressed” as it is taken out more carefully, but this has not been 
scientifically tested. The disadvantage with the open muscle biopsy technique is that it is 
more invasive and requires a larger skin incision 
compared to conventional muscle biopsy 
techniques, which increases the risk of post 
procedure infections. For the open muscle 
procedure, the subject is placed in a supine 
position and the skin of the thigh, overlaying the 
site of the muscle biopsy is washed with 
antiseptics. Local anaesthesia and a 4 cm skin 
incision is applied approximately 15 cm lateral 
and cranial of the patella. The muscular fascia of 
the vastus lateralis is visualized and carefully 
divided without disturbing the underlying muscle 
(Figure 8). 
Figure 8. The open muscle biopsy procedure. 
A muscle biopsy (2 g) is excised and directly 
placed in room temperature oxygenated Krebs-
Henseleit buffer containing 5mM HEPES and 
0.1% bovine serum albumin (BSA; RIA Grade; 
Sigma St Louis, MO) for subsequent in vitro 
experiments. It is important to handle the biopsy 
carefully, ensuring that the fibres are not 
stretched, as this can disturb the muscle 
homeostasis and handling may increase glucose 
uptake. After haemostasis, the muscle fascia and 
the skin are sutured with self-dissolving sutures. 
The open muscle biopsy consists of a long 
portion of intact muscle fibres that can 
subsequently be divided into smaller muscle 
strips (10-20 mg each) and attached to plastic 
clamps (Figure 9).  
 
Figure 9. Muscle strips attached to clamps 
ready for incubation. 
The muscle strips can then be incubated with different compounds and further studied for 
DNA methylation and mRNA expression analysis as described in papers 2 and 3.  
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3.2.2 Muscle biopsy technique by conchotome 
In paper 4 and for the in vivo studies in paper 2, a conchotome was used to collect the 
muscle biopsies. For this procedure, the skin is washed and local anaesthesia is applied as in 
the open muscle biopsy procedure. A small skin incision is made overlaying the vastus 
lateralis muscle and a Weil-Blakesley conchotome (Figure 10) is introduced through the skin 
to obtain the muscle biopsy (100 mg).  
 
Figure 10. Weil-Blakesley conchotome. 
Several samples can be collected through the same incision and the wound does not require 
suturing. Compared with the open muscle biopsy technique, this technique is technically 
easier to perform and it is less invasive. As the skin incision is smaller, the risk of post 
procedure infection is low. The amount of tissue obtained is smaller and because the biopsy is 
taken out blindly, it is less intact in comparison to the open muscle biopsy.  
 
3.3 Cell cultures 
3.3.1 Human primary skeletal muscle cell culture 
Cell culture systems are useful tools for validation of results found in human tissues and for 
mechanistic studies. In paper 2 and 3, we used human primary skeletal muscle cell cultures 
that originate from biopsies obtained during the “open muscle biopsy” from donors described 
in Table 3. Primary skeletal muscle cells or satellite cells are muscle-specific stem cells that 
are located between the basal lamina and sarcolemma of the muscle fibres. Satellite cells are 
isolated and purified from the skeletal muscle by trypsin and collagenase digestion, grown as 
myoblasts, and differentiated into myotubes (Al-Khalili et al., 2003). An advantage with 
primary skeletal muscle cells is the human origin, and aspects of the metabolic phenotype of 
the donor is retained also in the culture (Boyle, Zheng, Anderson, Neufer, & Houmard, 
2012). Our group has shown that human primary skeletal muscle cells from type 2 diabetic 
donors also show insulin resistance (Bouzakri & Zierath, 2007). This is a key advantage 
when studying the mechanisms underlying insulin resistance in skeletal muscle. Primary cell 
cultures have a limited life span and stop proliferating after a number of cell divisions. The 
purification process is challenging and often other cell types such as fibroblasts can be 
difficult to eliminate. Fibroblasts grow faster than myoblasts and can become prominent in 
the culture, complicating the muscle data analysis. The specific methods for the muscle 
culturing and different media used are described in detail in the Methods sections in paper 2 
and paper 3. 
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3.3.2 Rat L6 skeletal muscle cell culture 
The rat L6 is a commercially available immortalized cell line purchased from ATCC (Wesel, 
Germany). Cell lines proliferate faster than primary cell cultures and are more resistant to 
external stress, making cell lines technically easier and faster to grow. In comparison to 
primary cell cultures that originate from different donors, a cell line stems from a single 
donor where the culture has been immortalized. Results obtained from a cell line are often 
more reproducible, but it is important to bear in mind that the results only represent effects 
noted in one individual. In contrast, validation in primary cultures provides insight into 
different responses between subjects. In paper 3, we used both human primary skeletal cells 
and rat L6 cells to demonstrate the effects of AICAR on reducing cytokine mRNA. Detailed 
methods of growth, differentiation and medias used for the rat L6 muscle cells can be found 
under “Methods and Materials” in paper 3.  
3.4 Small interfering RNA (siRNA) 
When studying the cellular function of a specific gene, it can be useful to selectively 
modulate the expression of that gene. Inhibition of gene expression can be achieved by using 
synthetic small or short interfering RNA molecules (siRNA). Synthetic siRNA are small (25 
nucleotides) double-stranded RNA molecules that can be transfected into cell cultures to 
transiently silence a gene of interest. Inside the cell, the siRNA associates with RNA-induced 
silencing protein complex (RISC), a multi-protein complex that gets activated after an ATP-
dependent unwinding of the siRNA. After activation, one of the strands of the siRNA is 
retained within the RISC, binds the messenger RNA target by perfect pairing. Once siRNA 
has bound to the target, it is cleaved and degraded (Figure 11).  
 
Figure 11. siRNA mechanism of silencing mRNA in the cell. 
Although a major portion of the mRNA is degraded, there will usually be some remaining 
mRNA that avoids the degradation and this may be sufficient in some cases for ensuring 
cellular function. The siRNA sequences are specific to their target but may have off-target 
effects, meaning that they may also silence other genes. New techniques such as CRISPR-
Cas9 are available to completely silence a gene, however, the siRNA technique still has its 
advantages of being easy to use, cost efficient and well tolerated by the cells. siRNAs were 
used in paper 2 and 3, the details of the experiments can be found in the “Methods and 
Materials” section of each respective manuscript.  
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3.5 Metabolic assays 
In vitro systems allow for the determination of the metabolic function of skeletal muscle 
strips or cells exposed to a certain treatment. In paper 2, fatty acid oxidation as well as 
glucose incorporation into glycogen assays were conducted to see if the silencing of DAPK3 
has an impact on metabolism. The methods of these metabolic assays are previously 
described in detail by our group (Al-Khalili et al., 2006). 
3.6 DNA and RNA extraction 
DNA and RNA have been extracted using column based extraction kits according to the 
protocol from the manufacturers. Several different extraction kits (DNeasy, RNeasy, AllPrep 
kit (all from Qiagen, Hilden, Germany), E.Z.N.A (Omega Bio-tek, Norcross, GA, USA) and 
mirVana (Thermo Fisher Scientific, Waltman, MA, USA) have been used throughout this 
thesis depending on the availability in the laboratory at that specific time. DNA and RNA 
concentrations were measured by Spectrophotometry (NanoDrop1000 by Thermo Fisher 
Scientific). Details of DNA and RNA extractions can be found in the Methods section of each 
manuscript.  
3.7 mRNA expression analysis 
RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription kit 
(Thermo Fisher Scientific). Quantitative PCR was performed using SYBR Green-based 
primers in paper 2 and Taqman probes in papers 3 and 4. Primers are listed in the respective 
manuscripts.  
In paper 4, RNA samples were subjected to gene microarray analysis using Human Gene 2.1 
ST Array (Affymetrix, CA, USA) performed by Bioinformatics and Expression Analysis 
(BEA) core facility at Karolinska Institutet.  
3.8 Immunoblot analysis 
Proteins were extracted and immunoblots were performed in papers 2 and 4 as described in 
each respective manuscript. The antibodies used are listed in each manuscript and have been 
validated in our laboratory and used in previous publications from our group.  
3.9 Studies of DNA methylation 
To date, there are many different ways to measure DNA methylation. The technique used 
depends on several things, the quality and amount of the DNA, if one is interested in a 
particular gene or the whole genome, cost of the analysis, equipment and skills for data 
interpretation (Kurdyukov & Bullock, 2016). We used different techniques in papers 1 and 2, 
and will here be closer described to clarify the differences.  
3.9.1 Methylated DNA enrichment by MBD-capture 
In paper 1 we used a methylated DNA enrichment technique, the MethylMiner kit (Thermo 
Fisher Scientific, Waltman, MA, USA), where fragmented DNA is enriched by MBD-capture 
(Methyl-CpG-Binding Domain) using magnetic beads. The methylated DNA binds to the 
beads, while the unbound DNA, lacking methylation, is discarded in the supernatant (Figure 
12).  
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     Figure 12. Graphical presentation of the MethylMiner method. 
Target-specific DNA methylation can then be estimated by qPCR using specially designed 
primers. The level of DNA methylation is finally represented as the percentage of methylated 
DNA relative to input (total) DNA of each target measured by qPCR after the MBD-capture. 
The MBD captured methylated DNA can be used for subsequent sequencing of a large DNA 
sequence. The technique using qPCR and specially designed primers after MBD-capture does 
not, in contrast to sequencing, give the exact position of the methylated CpGs. However, 
when the gene of interest is known, as in paper 1, this enables a fast and easy way to estimate 
the level of DNA methylation. For details see the methods section of paper 1.  
3.9.2 Bisulfite conversion techniques 
In paper 2 we used two other techniques to measure DNA methylation. Here, in contrast to 
paper 1, we were interested in identifying all genes that were differentially methylated. Both 
techniques used in paper 2 are based on bisulfite conversion, which is considered the “gold 
standard” technique for DNA methylation analysis. The bisulfite treatment of DNA mediates 
deamination of non-methylated cytosine nucleotides into uracil, but has no effect on 5-
methylcytosine (methylated cytosine) residues. This induces a difference in DNA sequence, 
which can be recognized by hybridization with a microarray or by sequencing (Figure 13).  
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Figure 13. Cytosine is converted to Uracil. The 
bisulfite conversion changes the DNA sequence. 
In paper 2, we used bisulfite converted skeletal muscle DNA (Epitect Fast Bisulfite 
Conversion Kit by Qiagen) from a subset of subjects (n=3) for an Infinium 
HumanMethylation450 Bead Chip array (llumina, San Diego, CA, USA), to generate a list of 
differentially methylated genes, induced by insulin treatment. The bead chip microarray uses 
probes of more than 485 000 individual CpGs in 99% of known genes. Results obtained from 
microarrays may result in both false positive and false negative results, and thus subsequent 
technical validation, generally through target-specific sequencing is usually performed.  
Pyrosequencing (PyroMark CpG Assays from Qiagen) and individually designed primers 
were used to validate the results from the microarray. The pyrosequencer can read DNA 
sequences up to 100bp, and requires that the sequence is known. The advantage of the 
sequencing technique in comparison to the MethylMiner technique is the precision, giving 
the exact position of the methylated CpGs. However, the sequencing requires high quality 
DNA and as pointed out earlier, the sequence must be known. The MethylMiner technique on 
the other hand, can examine a larger sequence. For details of the microarray and 
pyrosequencing, including primer sequences, see the methods and results section in paper 2.  
3.10 Lipidomic analysis 
Lipidomic analysis enables the study of all the lipid classes and a majority of the specific 
lipid species in a tissue. In paper 4, we were interested in assessing if the lipid profile in 
skeletal muscle changed in obese subjects undergoing a diet intervention. Lipids were 
extracted from skeletal muscle (10 mg) by using the chloroform:MeOH (2:1 vol/vol) phase 
extraction method and were then analysed by ultrafast liquid chromatography-mass 
spectrometry- (LC-MS) based lipidomic analysis (Swedish Metabolomics Centre at the 
Swedish University of Agricultural Sciences in Umeå, Sweden). Lipid spectral count raw 
data were normalized to input muscle weight before analysis.  
3.11 Bioinformatics 
We have used bioinformatic approaches in papers 2, 3 and 4 included in this thesis.  In 
paper 2, we used a methylation microarray (Infinium HumanMethylation450 Bead array by 
Illumina) to identify novel gene targets that were differentially methylated by insulin 
treatment. The data analysis was performed at Bioinformatics and Expression Analysis 
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(BEA) core facility at Karolinska Institutet. In paper 3, we used a bioinformatic approach to 
identify transcription factors possibly involved in the basal expression of IL-6 and LIF. The 
database dcode.org (Ovcharenko, Nobrega, Loots, & Stubbs, 2004) was used to identify 
conserved and putative functional regions of the cytokine promoter. We used open access 
expression microarrays (for GEO accession number see Supplementary table of paper 3) to 
allow exclusion of transcription factors that were not expressed in human or rat skeletal 
muscle tissue or cells. In paper 4, we performed a lipidomic analysis as well as an expression 
microarray analysis on human skeletal muscle biopsies before and after a diet intervention. 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed 
using Webgestalt (paper 2) (J. Wang, Duncan, Shi, & Zhang, 2013) and the Broad institutes 
GSEA software (paper 4) (Mootha et al., 2003).  
3.12 Statistics 
In most of the analysis throughout this thesis, we have compared tissues from the same 
individual or primary skeletal muscle cell donor, allowing for paired statistical testing. After 
testing the normal distribution with Shapiro-Wilk and D´Agostino-Pearson tests, a paired t-
test (normally distributed samples) or Wilcoxon signed rank test (not normally distributed) 
have been performed when there have been only two conditions to compare, and a two-way 
ANOVA with post hoc tests (when normally distributed) or Friedman´s test (not normally 
distributed), when there have been more than two conditions. Correlation analysis in paper 2 
was determined using Spearman correlation coefficient (not normal distribution) and Pearson 
correlation coefficient (normally distribution) was used in paper 3 and 4. Analysis was 
performed using GraphPad Prism version 7.0 (GraphPad software, Inc., La Jolla, CA, USA) 
or R (R, 2017). The significance level was set at <0.05. *p<0.05, **p<0.01 if not stated 
otherwise. Data is presented as mean±SEM if not stated otherwise.  
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4 RESULTS AND DISCUSSION 
4.1 DNA methylation is associated with metabolic changes 
DNA methylation patterns differ in skeletal muscle from people with type 2 diabetes and 
normal glucose tolerance (Barres et al., 2009). In adipose tissue, DNA methylation differs in 
people who respond well or poorly to caloric restriction for weight loss (Bouchard et al., 
2010). Exercise and weight loss through diet can modify genome wide DNA methylation in 
skeletal muscle (Brons et al., 2010; Jacobsen et al., 2012; Ronn & Ling, 2013). More 
specifically, acute exercise as well as cytokines, and free fatty acids can remodel promoter 
methylation and gene expression of metabolically important genes such as PPAR, PDK4 and 
PGC1α (Barres et al., 2009; Barres et al., 2012). Differences in DNA methylation patterns in 
peripheral blood were identified between people with type 2 diabetes and non-diabetic 
subjects (Toperoff et al., 2012) and between obese and lean controls  (X. Wang et al., 2010). 
Weight loss by low calorie diet or a specific Mediterranean diet has also been shown to be 
associated with DNA methylation changes in peripheral blood (Arpon et al., 2016; Milagro et 
al., 2011). Collectively, this suggests that DNA methylation in skeletal muscle and blood may 
provide a mechanism for acute and transient as well as more long lasting gene regulation, 
which may have an impact on metabolic health. 
4.1.1 DNA methylation altered by diet-induced weight loss and RYGB 
Early metabolic improvements after RYGB surgery are likely to be partly mediated by the 
calorie restriction that patients undergo before and shortly after the surgery (Jackness et al., 
2013; Lim et al., 2011). We have previously shown that DNA methylation could constitute a 
regulatory mechanism contributing to the metabolic improvements after RYGB (Barres et al., 
2013). We were interested in studying if diet-induced weight loss could induce similar 
promoter DNA methylation changes as RYGB surgery. In addition, we were interested in 
finding if promoter DNA methylation alterations were present in peripheral blood, as this 
could enable a valuable proxy marker for improved metabolic health.  
In paper 1, 18 obese non-diabetic adults were recruited from the waiting list for gastric 
bypass. The subjects underwent a 14 day diet of 1,000 kcal per day (40-50% carbohydrate, 30-
40% protein, and 20% fat as percentage of total calories). On the last day of the diet, the obese 
patients underwent RYGB bariatric surgery. Peripheral blood was collected before and after 
the diet intervention and subsequent RYGB surgery and the promoter DNA methylation from 
the nucleated cells were studied. A subset of subjects (n=7) were followed up on the day of 
discharge (2 days after the surgery) and 12 months later. Six non-obese subjects undergoing 
elective cholecystectomy were also enrolled in the study to control for the surgical stress and 
to determine whether promoter DNA methylation in the obese cohort could be reversed by 
diet or RYGB to the level observed in non-obese subjects. The clinical characteristics of the 
study participants and the clinical chemistry at the various time points are presented in Table 
3.  
The obese subjects lost significant weight following the diet (4.2 kg1.4) and following the 
RYGB surgery (30 kg11.8), respectively. Glucose levels of the obese subjects after the diet 
were significantly reduced compared to before, and comparable to glucose levels of the non-
obese subjects, while the insulin levels in the obese subjects remained unchanged following 
the diet intervention. After the RYGB, the fasting plasma insulin levels were reduced 
compared to both before and after the diet. Collectively this indicates that the diet-induced 
weight loss had a modest effect on the glucose levels but a more profound weight loss, 
induced by RYGB, was needed to lower the insulin levels and thus to improve the HOMA-IR.  
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Type 2-diabetes was one of the exclusion criteria of the study and thus fasting glucose levels 
in the obese cohort were from the start of the study relatively low, the reason why we did not 
see a decrease. At discharge, both blood glucose and insulin levels were increased, both in the 
obese and the lean cohort. Surgery is known to induce transient insulin resistance and 
hyperglycaemia as a result of the surgical procedure itself that causes stress and inflammation 
in the body (Thorell, Efendic, Gutniak, Haggmark, & Ljungqvist, 1994) and our results could 
be a reflection of this process.  
Our group has previously demonstrated that the promoter regions of PDK4 and PGC1α, 
genes, important for substrate selection and mitochondrial function, are differentially 
methylated in skeletal muscle from obese subjects in comparison to skeletal muscle from non-
obese controls (Barres et al., 2013). Furthermore, the methylation levels of the promoter of 
these genes were restored to non-obese levels after RYGB-induced weight loss (Barres et al., 
2013). Using enrichment of genomic DNA with MBD-beads to capture the methylated DNA 
fraction and subsequent qPCR, the promoters of the genes PDK4, IL6 or TNF were not 
differentially methylated after the diet. Conversely, the promoter methylation of PGC1α was 
decreased after diet-induced weight loss (Figure 14, left). The promoter methylation of 
PGC1α also inversely correlated with plasma glucose and insulin levels after the diet, 
indicating that the promoter DNA methylation of PGC1α in peripheral blood may be used as a 
proxy marker for improved whole-body metabolic health. The decrease in promoter DNA 
methylation of PGC1α in our cohort in blood after diet is similar to the observed promoter 
DNA methylation decrease after RYGB in skeletal muscle (Barres et al., 2013). 
 
Figure 14. PGC1α (PPARGC1A) promoter methylation (left) and PDK4 promoter methylation (right), 
n=6-18. 
A year following the RYGB, the promoter DNA methylation of PDK4 and IL6 was increased 
in comparison to at the start of the study (Figure 14, right and Figure 15, left), suggesting 
that a substantial weight loss induced by RYGB, or another specific surgery-related factor, 
was needed to induce these DNA methylation changes. In contrast, the promoter methylation 
of PGC1α was unchanged in the blood a year after RYGB (Figure 14, left), in contrast to the 
findings in skeletal muscle (Barres et al., 2013). 
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Figure 15. IL6 (left) and TNF (right) promoter DNA methylation in peripheral blood, n=6-18. 
Interestingly, DNA methylation of all the investigated promoter regions presented here (except 
for TNF in lean cohort) was decreased early after surgery. This indicates, that factors like 
including the surgical stress, anaesthesia, and perhaps the total caloric restriction shortly 
before and after surgery, had a greater effect on DNA methylation than low calorie diet and 
RYGB respectively. We cannot exclude, that these DNA methylation alterations could be 
caused by a shift in nucleated blood cell types, and more reflect a general inflammatory state 
common after surgery (Jakeways et al., 1994) or anaesthesia (Heil, Silva, Pelosi, & Rocco, 
2017). This hypothesis is strengthened by the fact that also the non-obese subjects undergoing 
cholecystectomy demonstrated similar promoter DNA methylation changes.  
We measured the plasma cytokine concentrations of IL-6, TNFα and IL-8 before and after the 
diet and at discharge. We did not find any changes in plasma IL-6 or TNFα levels that 
correlated with the alterations in IL6 and TNFα promoter DNA methylation, although there 
was a trend for plasma IL-6 to increase after surgery. Several tissues produce and secrete IL-6 
and other cytokines into the blood stream, thus the cytokine levels we measured in plasma in 
our cohort do not necessarily reflect the promoter DNA methylation levels in nucleated blood 
cell DNA. A weakness in our study is the inability to measure and interpret mRNA in relation 
to the DNA methylation in the blood. Only nucleated white blood cells have DNA, while all 
blood cells including the red blood cells have mRNA (Kabanova et al., 2009). Thus mRNA of 
peripheral whole blood would not reflect the changes in DNA methylation. Fluorescence 
activated cell (FAC) sorting of blood cell types prior to the analysis may solve this dilemma 
for future studies.  
In paper 4, we studied a different cohort consisting of eight obese, non-diabetic subjects 
undergoing the same dietary regime of 1,000 kcal/day for a three-week duration. The clinical 
characteristics are described in Table 3, and are comparable to the obese cohort in paper 1. A 
three-week dietary intervention had a more profound effect on weight loss, fasting blood 
insulin levels and HOMA-IR than a two-week diet as expected. In contrast, the fasting glucose 
levels were not significantly reduced after the three-week diet although the fasting glucose 
values were reduced to the same extent. This is likely due to the small size of this cohort (n=8) 
in comparison to the obese cohort of paper 1 (n=18).  
Muscle biopsies were obtained before and after the diet intervention and promoter DNA 
methylation of the same targets was measured with the same technique and the same set of 
primers as paper 1. Surprisingly, none of the promoters of IL6, PDK4 or PGC1α were 
significantly differentially methylated in skeletal muscle after diet intervention, although there 
were trends for decreased level of methylation for all targets (Figure 16, upper panel). The 
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skeletal muscle mRNA levels were increased for IL6 and PDK4, but not for PGC1α after the 
three-week low calorie diet (Figure 16, lower panel). Comparing the trends in decreased 
methylation and subsequent increases in mRNA of IL6 and PDK4, it is tempting to suggest 
that there could be a regulatory mechanism, although there is no statistical correlation. The 
promoter DNA methylation levels are very low in this cohort, with the exception of two 
subjects, and the relevance of small changes is questionable and perhaps present due to 
technical variation. Our cohort is small, and thus we cannot compare groups within the cohort. 
However, it is interesting that two of the subjects have an increased promoter DNA 
methylation in comparison to the other subjects, which is reduced to the level of the other 
subjects after the diet. Perhaps these two individuals could have a metabolically different 
response to obesity, although there is no correlation to clinical parameters. To further 
investigate such a hypothesis, a much larger cohort is needed.  
 
Figure 16. IL6, PDK4 and PGC1α promoter methylation (upper panel). IL6, PDK4 and PGC1α 
mRNA (lower panel) in human muscle before and after a three-week diet, n=8. 
The trend for a decrease in PDK4 promoter methylation and increased PDK4 mRNA 
expression gives an inverse relationship similar to previous results in skeletal muscle (Barres 
et al., 2013; Kulkarni et al., 2012), suggesting a possible regulatory mechanism of PDK4 
mRNA by DNA methylation. The discrepancies between our results from diet-induced weight 
loss and previous results in skeletal muscle from weight loss after RYGB (Barres et al., 2013) 
may be explained by the use of different technique to measure DNA methylation. We used a 
technique to enrich for methylated DNA and subsequent PCR, though others, including the 
study of skeletal muscle biopsies after RYGB, used techniques including bisulfite treatment of 
the DNA. This implies that we may have measured different regions of the gene promoter. 
Other factors may also have affected the degree of methylation, such as a greater weight loss 
after RYGB, surgery itself, or larger metabolic disturbances like in type 2 diabetes.  
In our cohort, PDK4 mRNA is increased after the low calorie diet, consistent with an earlier 
study (Pilegaard, Saltin, & Neufer, 2003). PDK4 is an enzyme that inhibits the pyruvate 
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dehydrogenase complex, which results in decreased carbohydrate oxidation and a shift in fuel 
selection towards lipid metabolism. Similarly, high fat diet (Peters et al., 2001) and exercise 
induces PDK4 expression in the normal glucose tolerant subjects (Pilegaard & Neufer, 2004), 
but no effect of exercise is seen in type 2 diabetic subjects (Kulkarni et al., 2012). PDK4 
mRNA levels are higher in type 2 diabetic patients (Kulkarni et al., 2012; P. Wu et al., 1999) 
and obese subjects (Barres et al., 2013) in comparison to healthy, lean controls. Insulin 
reduces PDK4 mRNA expression in normal-glucose tolerant individuals but not in type 2 
diabetics (Y. I. Kim, Lee, Choi, Lee, & Youn, 2006). In a state of type 2 diabetes with 
hallmarks of hyperinsulinemia and hyperglycaemia as well as high fatty acid levels, increased 
PDK4 expression leads to increased fatty acid oxidation but by inhibiting carbohydrate 
oxidation the hyperglycaemia is elevated even further, leading to a vicious circle. This process 
illustrates the metabolic dysfunction associated with type 2 diabetes.  
In conclusion, these results demonstrate that changes in DNA gene promoter methylation in 
response to interventions altering body weight are tissue specific and underscores the 
importance of studying DNA methylation directly in different tissues (Bell, 2017). Thus, it 
does not appear possible to use promoter DNA methylation in peripheral blood as a surrogate 
marker for gene methylation in skeletal muscle. Rather, changes in DNA methylation in 
peripheral blood can be used for predicting general metabolic changes. The subpopulation of 
blood cells will influence the epigenetic pattern in blood and thus sorting of blood cells could 
overcome this issue. Promoter methylation of metabolically important genes may constitute a 
molecular regulatory mechanism contributing to the metabolic improvements after RYGB 
surgery.  
Peripheral blood is readily accessible and does not require invasive techniques. Nutritional 
markers in blood are warranted as this could enable a strategy of risk evaluation and 
personalised medicine. However, DNA methylation pattern differ between tissues and thus a 
blood sample may not fully substitute for the study of the specific tissues. Investigation to 
increase knowledge about gene regulation in specific tissues contributing to metabolic 
dysfunction is of major importance for enabling better treatments. However, peripheral blood 
could be used as general metabolic markers and as guidance for personalised health advice and 
risk assessment where invasive sampling techniques are unsuitable.  
In paper 1, we studied the promoter DNA methylation of metabolically important genes after 
negative energy homeostasis induced by weight loss. In paper 2, in contrast, we were 
interested in the acute effects of insulin and glucose ingestion on DNA methylation in skeletal 
muscle.  
4.1.2 DNA methylation is altered acutely by insulin and glucose exposure 
In paper 2, we hypothesized that insulin treatment could acutely alter the genomic DNA 
methylation pattern in human skeletal muscle. Intact human skeletal muscle strips derived 
from open muscle biopsies from healthy, lean donors (Table 3) were incubated in vitro with 
or without (basal) insulin for one hour. The muscle strips were then frozen immediately for 
subsequent DNA extraction and bisulfite conversion. The differentially methylated genes were 
studied using a genome-wide Illumina 450k array.  
Insulin treatment induced broad DNA methylation changes throughout the genome. A KEGG 
analysis of all the differentially methylated genes revealed that pathways of insulin signalling, 
type 2 diabetes and metabolic pathways were significantly changed. This suggests that acute 
insulin treatment does affect the methylation signature of metabolic genes and that this could 
be a regulatory mechanism for changed gene expression important for metabolic homeostasis.  
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One specific gene target, DAPK3 (Death-associated protein kinase 3), was selected for further 
investigation due to consistent changes in DNA methylation between basal and insulin treated 
muscle strips (18% change between beta-values, p=0.006). DAPK3 is known to play a role in 
autophagy (Komatsu & Ikebe, 2004) and apoptosis (Kawai, Matsumoto, Takeda, Sanjo, & 
Akira, 1998) and has been identified as a tumor suppressor gene, frequently mutated or 
methylated in several cancer types (Brognard, Zhang, Puto, & Hunter, 2011). However, 
DAPK3 is previously unknown to be involved in skeletal muscle metabolism. Pyrosequencing 
was performed to validate the changes in the array and confirmed that the methylation of one 
specific CpG site (cg08498987) in the gene body of DAPK3 was increased in the insulin 
treated samples (Figure 17, left). However, mRNA of DAPK3 remained unchanged in the 
muscle strips (Figure 17, right).  
 
Figure 17. DNA methylation changes of DAPK3 (left) mRNA of DAPK3 (right), n=10. 
DNA methylation of DAPK3 was then studied in skeletal muscle biopsies, from a separate 
cohort including normal glucose tolerant and type 2 diabetic men, before and 2-h after an oral 
glucose challenge (Table 3). The methylation level of DAPK3 at the same CpG site was lower 
at baseline in the type 2 diabetic than in the normal glucose tolerant subjects (Figure 18, left). 
After the glucose challenge, the methylation level was reduced in both groups. The blood 
glucose concentration at the 2-h time point after the glucose challenge was inversely correlated 
with the methylation level of DAPK3 (Figure 18, right).  
 
 
 
 
 
 
 
Figure 18. DAPK3 DNA methylation in skeletal muscle from subjects with normal glucose tolerance 
(NGT) and type 2 diabetes (T2D) before and 2-h after an oral glucose tolerance test (OGTT) (left) 
DAPK3 methylation changes after OGTT correlated with post OGTT glucose values (right). Open 
circles, NGT and closed squares, T2D. n=12. * Main effect of OGTT. † indicates the main effect of 
T2D.  
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Collectively this identifies that DNA methylation of a previously unknown gene target is 
regulated by changes in glucose and insulin levels and altered in type 2 diabetes. Moreover, 
this study demonstrates the rapid and transient changes in DNA methylation, induced by 
insulin and glucose, illustrating the dynamic regulative mechanism of DNA methylation.  
To investigate the metabolic relevance of DAPK3 in skeletal muscle, we silenced DAPK3 
using siRNA in primary human myotubes and performed metabolic assays. Glucose 
incorporation into glycogen was unchanged in primary myotubes transfected with siRNA 
against DAPK3. Conversely, both basal and AICAR-challenged lipid oxidative capacity was 
increased when DAPK3 was silenced, suggesting that DAPK3 could be involved in 
suppressing lipid oxidation in skeletal muscle.  
The mRNA of DAPK3 was not changed in any of the samples, highlighting the complex 
relationship between DNA methylation and subsequent effects on gene regulation. Perhaps the 
level of DAPK3 DNA methylation changes noted here is not sufficient to regulate 
transcription. The muscle strips were frozen after 1h insulin incubation and it is possible that 
the mRNA expression changes in the muscle occurred at a later time point. However, DNA 
methylation does not always correlate with changes in mRNA (Barres et al., 2013; Multhaup 
et al., 2015). Additional involvement of other epigenetic modifications, such as histone 
modifications, may be required to fully regulate DAPK3 mRNA expression.  
This study underscores the dynamic features of DNA methylation. It demonstrates that both 
short insulin treatment in vitro of intact human muscle strips, and glucose ingestion in vivo can 
induce acute DNA methylation changes in skeletal muscle. Further studies are needed to 
reveal the relevance of these transient and dynamic methylation changes for skeletal muscle 
metabolism and health.  
In summary, both paper 1 and paper 2 highlight DNA methylation as a potential regulatory 
mechanism for metabolically important genes. We, and others, demonstrate that 
environmental factors such as weight loss, surgical stress, exercise and nutrition can induce 
tissue-specific rapid, transient, but also more long-term, epigenetic marks that can influence 
metabolic health. This enables the identification of potential targets for disease prevention and 
treatment. However, epigenetic regulation is complex and multileveled and there are still 
questions about the precise mechanism of regulation and its causative role in metabolic 
disease.  
 
4.2 AICAR-induced AMPK activation and cytokine mRNA in skeletal muscle  
Energy homeostasis and inflammation are tightly regulated and perturbations in one system 
affect the other. Activation of AMPK, a central regulator of cell energy homeostasis, has anti-
inflammatory effects, but the underlying mechanisms are not fully elucidated. In paper 3, we 
aimed to study the regulatory mechanisms of AICAR-induced AMPK activation on cytokine 
mRNA expression in healthy skeletal muscle. Study of skeletal muscle from people with 
normal glucose tolerance can aid in the identification of the mechanisms by which energy and 
inflammatory systems are interconnected, and dissect dysfunction in metabolic disease.  
Thirteen healthy, non-obese men were recruited for an open muscle biopsy (Table 3). The 
muscle biopsy was subsequently dissected into intact muscle strips and incubated in vitro with 
or without AICAR (2 mM) for one hour and subsequently frozen in -80 °C for further mRNA 
studies. AICAR is often used in experimental settings as an exercise-mimicking agent as it, in 
similarity to exercise, strongly activates AMPK (Corton, Gillespie, Hawley, & Hardie, 1995). 
Exercise induces PGC1α, PDK4 and TFAM mRNA expression (Egan et al., 2010; Short et al., 
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2003), and thus we were expecting to see an increased mRNA response also with AICAR. 
Surprisingly, the mRNA of PGC1α, PDK4 and TFAM 
remained unchanged by the AICAR treatment (Figure 19).  
 AICAR is an AMP-analogue, mimicking a signal of low 
cellular energy, which is only part of the exercise stimuli. 
Indeed, our group has previously shown that PDK4 mRNA 
is induced in skeletal muscle cells by calcium release 
induced by caffeine incubation, but not by AICAR 
incubation (Kulkarni et al., 2012). Thus, another factor other 
than increased AMP/ATP ratio is the regulative stimuli for 
PDK4 expression. Maybe calcium release, which is also part 
of the exercise stimuli, is responsible for the exercise-
induced change in PDK4 expression. In contrast, AMPK is 
a specific inducer of PGC1α mRNA (Jager, Handschin, St-
Pierre, & Spiegelman, 2007) and this AMPK-mediated 
induction of PGC1α is suggested to play a major role in the 
improved mitochondrial function in response to exercise.  
Figure 19. mRNA of metabolic 
targets in human skeletal muscle 
biopsies treated with and without 
AICAR (2 mM) for one hour, n=13.  
Since the muscle strips were only incubated with AICAR for one hour and the experiment was 
terminated immediately after the incubation, longer incubation time with AICAR or a later 
termination time point may have revealed changes in PGC1α and TFAM mRNA. This is in 
line with previous results from our group demonstrating that TFAM and PGC1α mRNA do not 
increase until two hours and three hours post ex vivo contraction in mice, and at three hours 
post exercise (PGC1α) in human subjects (Barres et al., 2012) respectively. In conclusion, it is 
likely that we studied mRNA of the above metabolic targets at a time point that was too early 
to see any significant changes.  
In contrast to the metabolic targets, mRNA of all the cytokines we tested were reduced 
(Figure 20). Cytokine mRNAs are constitutively expressed in skeletal muscle at low levels as 
demonstrated in the figure below based upon publically available expression arrays (Figure 
21). AICAR exposure has previously been shown to reduce baseline cytokine mRNA and 
protein in mice skeletal muscle and human skeletal muscle cells (Glund et al., 2009). We 
confirmed these findings through in vitro incubations of intact human muscle strips, as well as 
human skeletal muscle cells and rat L6 cells.  
 
Figure 20. mRNA of cytokine targets in human skeletal muscle 
biopsies treated with and without AICAR (2 mM) for one hour, n=13. 
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Figure 21. Cytokine gene expression in Human and Rat tissue and cells based on publically available 
array databases generated by a free web-based tool (Pillon, 2017).  
This acute effect on cytokine expression could constitute a mechanism by which AMPK 
reduces tissue inflammation. The inflammatory process requires energy and since the main 
role of AMPK is to restore ATP in the cell, reducing production of cytokines may be an 
efficient mechanism to save energy.  
We aimed to elucidate the mechanism by which AICAR reduces cytokine mRNA. We 
decided to focus on IL-6 and LIF as these cytokines were expressed in both human and rat 
cells, and are typical “immunometabolic” genes in comparison to the more pro-inflammatory 
genes IL-1β and TNFα. IL-8 is not expressed in rat and was not studied further. IL-6 and LIF 
belong to the same structural class of cytokines and have overlapping activities as they have 
specific binding receptors, but share a common signal-transducing receptor gp130 (Taga & 
Kishimoto, 1997). LIF has mainly been appointed a function in muscle development and 
regeneration (Brandt et al., 2015; Broholm et al., 2011; Spangenburg & Booth, 2006) but 
recently LIF has also been suggested a role in skeletal muscle metabolism (Brandt et al., 
2015).  
To determine if AICAR is likely to decrease cytokine mRNA by degradation or by inhibiting 
transcription, we designed an experiment where we exposed rat L6 muscle cells to either the 
transcription-inhibiting agent Actinomycin D alone or together with AICAR. Actionmycin D 
reduced IL-6 mRNA as expected. Adding AICAR to Actinomycin D, did not decrease the 
mRNA further than with Actinomycin D alone (Figure 22). Thus, we concluded that AICAR 
is likely reducing cytokine mRNA through inhibiting transcription.  
 
 
Figure 22. L6 cells were treated with Actinomycin D alone or with AICAR and mRNA expression 
of Il6 (left) and lif (right) was assessed. Results are mean±SEM (n=4). 
 
IL
6
LI
F
IL
1B
TN
F
IL
8
0
1
2
3
4
E
x
p
re
s
s
io
n
 r
e
la
ti
v
e
 t
o
 m
e
d
ia
n
Human Cell Human Tissue Rat L6 Rat Tissue
0 10 20 30 40 50 60 70
0.0
0.2
0.4
0.6
0.8
1.0
Time (min)
R
e
la
ti
v
e
 I
l6
 m
R
N
A
Act D
Act D+AICAR
0 10 20 30 40 50 60 70
0.0
0.2
0.4
0.6
0.8
1.0
Time (min)
R
e
la
ti
v
e
 l
if
 m
R
N
A
Act D
Act D+AICAR
 34 
Transcription of eukaryotic genomic DNA to mRNA requires the enzyme RNA polymerase II 
and several transcription factors and cofactors. Transcription factors are proteins that bind to a 
promoter sequence and initiate a series of interactions with other cofactors that together form 
the transcriptional complex, to which RNA polymerase II can bind and transcribe the specific 
sequence. Sequence specific transcription factors are considered the most important and 
diverse mechanism of gene regulation. Other regulatory mechanisms that can affect 
transcription are epigenetic marks as discussed earlier in this thesis.  
A classical inflammatory signalling pathway includes translocation of the p65/RELA subunit 
of the NFκB transcription factor into the cell nucleus and subsequent binding to NFκB 
response elements, which will initiate transcription of inflammatory genes such as IL6. 
However, exercise-induced IL-6 production can be regulated independently of the NFκB-
pathway by the JNK/AP-1-pathway in mouse skeletal muscle (Whitham et al., 2012) and by 
the p38 MAPK/CREB pathway in cardiac fibroblasts (Du et al., 2005). The IL6 promoter 
contains known binding sites for several transcription factors NFκB, AP-1, CREB and C/EBP 
and RBPJ (Luo & Zheng, 2016; Vanden Berghe, De Bosscher, Boone, Plaisance, & 
Haegeman, 1999; Welc & Clanton, 2013). Thus several transcription factors may play a role 
in the AICAR-induced transcriptional effect upon cytokine mRNA. 
Complementary to the transcription factors known from the literature to regulate IL6 and LIF 
mRNA expression, we were interested in finding previously unknown factors that could be 
involved in the transcription of these targets. Thus, we used an unbiased bioinformatics 
approach. Taking advantage of the fact that AICAR reduces IL6 and LIF in two different 
species, in human and rat, we identified conserved regions in the promoters of IL6 and LIF 
between human and rat. We listed the transcription factors that bind to these promoter regions 
of IL6 and LIF respectively and then overlapped the list, reducing the candidates to 15 
common transcription factors. The previously known transcription factors from the literature 
were added to the list. Using a database with publically available expression arrays we could 
then exclude the candidates that were not expressed in skeletal muscle, which finally resulted 
in a list of 8 transcription factor candidates. This work process identified three, in the context 
of metabolism, new transcription factors, Nfyc, Sp1 and Zbtb14 (Figure 23).   
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Figure 23. Schematic illustration of the process of identifying new potential transcription factors. 
Using specific siRNA sequences, we silenced each one of the eight transcription factors 
candidates in L6 cells and subsequently treated them with AICAR to determine the IL6 or LIF 
mRNA. Silencing RELA, JUN, NFYC, CREB1, ZBTB14, RBPJ and CEBPB, was without 
effect in the AICAR-mediated decrease of IL6 and LIF mRNA. However, when silencing SP1, 
the AICAR-reducing effect on IL6 mRNA was blunted, indicating that this transcription factor 
may be involved (Figure 24).  
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Figure 24. Il6 mRNA in rat L6 skeletal muscle cells treated with siRNA for Sp1 and then 
incubated with or without AICAR (2 mM) for 1 hour (left). Individual change in IL6 mRNA 
reduction with AICAR-treatment (right), n=4. 
Sp1 was identified in the 1980’s and was the first ever transcription factor to be purified 
(Kadonaga & Tjian, 1986). Sp1 is a housekeeping-type of transcription factor, meaning that it 
is involved in constitutively transcribed genes. It interacts with NFκB/Rela factors and can 
provide a regulative factor for constitutive expression of NFκB genes (Hirano et al., 1998). 
The silencing effect of Sp1 achieved in the L6 cells was about 50%, however, despite this 
modest reduction on Sp1, there was a significant blunting of the AICAR effect on IL6 mRNA. 
More pronounced reduction of Sp1, may have resulted in a more complete inhibition of the 
AICAR effect. However, silencing more than 50% of housekeeping genes are often difficult to 
achieve, and not compatible with cell survival (personal communication with Nicolas J 
Pillon).  
Interestingly, when silencing the relatively 
unknown transcription factor Zbtb14, the 
baseline LIF mRNA was increased three-
fold (Figure 25), suggesting that this factor 
is involved in the regulation of LIF 
expression. LIF has, besides its 
involvement in muscle and nerve 
regeneration, also gained attention in the 
cancer field as a bad prognostic factor in 
several cancers including colorectal and 
breast cancer (Nicola & Babon, 2015; Yue, 
Wu, & Hu, 2015). Our observation, of the 
involvement of ZbtB14 in the regulation of 
LIF may be of importance in the cancer 
field in understanding the oncogenic 
properties. 
Figure 25. Lif mRNA in rat L6 skeletal muscle cells after 
treatment with siRNA against the transcription factor 
Zbtb14 and subsequent incubated for 1 hour with or 
without AICAR (2 mM), n=4.  
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In conclusion, we demonstrate that AICAR, mimicking a low energy state in skeletal muscle, 
robustly reduces baseline mRNA of several cytokines. Through a bioinformatics approach and 
siRNA silencing experiments we identify Sp1 transcription factor as involved in the regulatory 
mechanism of AICAR-induced reduction of IL-6. In addition, we identify a new transcription 
factor Zbtb14 as involved in the transcriptional regulation of LIF.  
 
4.3 Obesity, diet and effect on mRNA and lipid profile in skeletal muscle 
Skeletal muscle metabolism is impaired in the obese state, resulting in insulin resistance. 
There is evidence for the involvement of intra-myocellular lipid accumulation and tissue 
inflammation in this process. In paper 1, we demonstrated that obese, insulin resistant 
subjects improve their fasting insulin levels and HOMA-IR after substantial weight loss. In 
paper 4, we aimed to investigate if weight loss in obese insulin resistant subjects could result 
in altered skeletal muscle lipid and gene expression profiles. Eight obese, non-diabetic but 
insulin-resistant subjects were recruited from the waiting list of patients scheduled for RYGB 
surgery at Danderyd Hospital to enrol in the study. The subjects underwent a three-week low 
calorie diet intervention (1,000 kcal/day). Muscle biopsies were obtained after a 12 h fast and 
clinical chemistry was determined before and after the diet intervention (Table 3).  
The subjects lost significant weight (average 8±3.5 kg) and improved fasting insulin, HbA1c, 
triglycerides, cholesterol and LDL levels after the diet intervention (Table 3). Thus, the three 
week low calorie diet was efficient in improving whole-body metabolic health similar to 
results of other diet intervention studies in insulin resistant and type 2 diabetic subjects (Jazet 
et al., 2008; Lara-Castro et al., 2008; Lim et al., 2011). A three-week diet intervention was 
also as expected, more efficient in reducing insulin levels than a two-week diet intervention 
but not as powerful as the weight loss after RYGB as described in paper 1 (Table 3).  
We performed a gene expression microarray analysis to identify altered gene expression after 
the diet intervention. KEGG analysis showed enriched pathways of oxidative phosphorylation 
and surprisingly also inflammation. Most of the genes in the expression array were 
upregulated (35 genes that were significantly up and one down) (Figure 26). 
 
Figure 26. Diet-induced changes in mRNA expression in human skeletal muscle. Mean±SD, n=8. 
The diet-induced weight loss and concomitant whole-body metabolic changes were associated 
with a substantial effect on gene transcription. More specifically, genes involved in fatty acid 
transport or metabolism were among the most changed in the expression array. SLC27A1, 
also named FATP1, is a long fatty acid transporter. Skeletal muscle from obese adults is 
associated with increased uptake of long fatty acids (Bonen et al., 2004). Overexpression of 
FATP1 in rat skeletal muscle increased fatty acid uptake concomitant with increased fatty acid 
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oxidation (Holloway et al., 2011). In contrast, overexpression of another fatty acid transporter, 
FAT/CD36, similarly increases the fatty acid uptake, but instead increases the esterification 
and storage of fatty acids (Garcia-Martinez et al., 2005). Thus, this indicates that an increased 
FATP1 expression in skeletal muscle after the diet intervention could reflect an increased fatty 
acid uptake of lipids that are destined for fatty acid oxidation rather than storage.  
Mitochondrial malonyl-CoA decarboxylase (MLYCD), that catalyses the conversion of 
malonyl-CoA to acetyl-CoA, is upregulated in skeletal muscle after the diet intervention. 
Deletion of MLYCD shifts oxidation of metabolic substrates from lipids to glucose (Bouzakri 
et al., 2008). PDK4 suppresses conversion of pyruvate to acetyl-coA, the rate-limiting step in 
glucose oxidation, diverting fuel selection towards fatty acid oxidation. Thus, increased 
expression of both MLYCD and PDK4 promotes fatty acid oxidation. 
The uncoupling protein 3 (UCP3) is upregulated in skeletal muscle in response to the weight 
loss in our study, consistent which the literature (Hildebrandt & Neufer, 2000). UCP3 is 
skeletal muscle specific and suggested to have a role to protect the muscle against oxidative 
damage induced by mitochondrial production of reactive oxygen species (Echtay et al., 2002). 
More specifically, UCP3 may act as a transporter of fatty acids out of the mitochondria, to 
ensure that the delivery of fatty acids into the mitochondria matrix does not exceed the 
capacity to oxidize (Dulloo & Samec, 2000). As fatty acid oxidation in the mitochondria is 
likely to be increased in the skeletal muscle after the diet intervention, the increased 
expression of UCP3 could enable a protective mechanism against reactive oxygen species that 
are produced by the mitochondria as a by-product.  
Stearoyl-CoA desaturase-1 (SCD1), an enzyme involved in the biosynthesis of fatty acids, is 
downregulated in the muscle biopsies after the diet intervention, which has been described 
previously (Dube et al., 2011). Obesity is associated with increased SCD1 expression, 
accumulation of triglycerides and reduced β-oxidation in skeletal muscle (Hulver et al., 2005). 
However, also highly trained athletes exhibit an increased SCD1 expression (Goodpaster, He, 
Watkins, & Kelley, 2001) and exercise training increases SDC1 expression, associated with 
improved insulin sensitivity (Schenk & Horowitz, 2007). The decreased SCD1 levels in our 
study may reflect the shift 
toward increased 
oxidation and thus 
decreased storage of fats. 
Collectively our gene 
expression data indicates 
that genes promoting lipid 
oxidation are increased in 
the skeletal muscle after 
the diet intervention 
(Figure 27). However, we 
do not know if the altered 
gene expression is a cause 
or a consequence of the 
decreased insulin levels.  
 
Figure 27. Expression of genes promoting fatty acid oxidation is up-
regulated after the diet.  
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To study the change in skeletal muscle lipid profile after the diet intervention, we performed a 
lipidomic analysis. We found that total lipids within each lipid class were unaltered after the 
dietary intervention. However, several specific lipid species were significantly reduced after 
the diet intervention. Most of the changed lipid species were from the phosphatidylcholine 
(PC) and triglyceride (TG) class (Figure 28).  
 
 
Figure 28. Alterations in specific lipid species in human skeletal muscle after dietary 
intervention. Mean±SD, n=8. 
PC and phosphatidylethanolamine (PE) are phospholipids important for membrane 
composition and integrity and stands for 50% and 20-30% respectively of the phospholipid 
pool of the membrane (Takagi, 1971). An altered relationship of the phospholipids can change 
the membrane fluidity and thereby the signalling and transportation of molecules and nutrients 
across the cell membranes. Alterations of the PC and PE species are associated with insulin 
resistance (Newsom et al., 2016).  
Ceramide and sphingomyelin (SM), both belonging to the sphingolipid class, are important for 
cell membrane structure, but have also been recognized as signalling molecules (Hannun & 
Obeid, 2008). Mainly ceramide species, but also sphingomyelins, have been appointed 
relevance in the development of insulin resistance (Chavez et al., 2014; Li et al., 2011). 
Diacylglycerol (DAG) species have also been implicated in the development of insulin 
resistance (Itani, Ruderman, Schmieder, & Boden, 2002). However, in our cohort DAG 
species were unaltered.  
To estimate the relevance of the identified 24 lipid species in our cohort and the relationship to 
clinical parameters, we compared each one of the lipid species to LDL, HDL, triglycerides, 
insulin, BMI and HOMA-IR (Figure 29).  
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 Figure 29. Altered lipid species after dietary intervention and their correlation  
 to clinical parameters. Mean±SD, n=7-8. 
 
Four species, PE(36:1), SM(d18:1/20:0), TG(54:0) and TG(56:0) were correlated with insulin 
levels and HOMA-IR, indicating that these specific lipid species may play a role in the 
ameliorations of insulin resistance after the diet intervention. These lipid species are not 
previously described in the literature, and further investigation is needed to fully understand 
their relevance for skeletal muscle metabolism and development of insulin resistance.  
Recently several papers on the muscle lipid profile have been published. Skeletal muscle and 
plasma lipid profiles were compared between lean and obese subjects with and without insulin 
resistance (Tonks et al., 2016). The authors found that Cer(d18:1/18:0) was the only species 
associated with insulin resistance in skeletal muscle. However, they identified PC(0-34:3) in 
skeletal muscle as associated with obesity per se (Tonks et al., 2016). Interestingly, in our 
cohort, PC(0-34:4), a closely related lipid species, correlated inversely with BMI, but not 
insulin. Another study of obese subjects undergoing RYGB surgery with or without a prior 
exercise regime, identified a total decrease of skeletal muscle ceramide content after the 
RYGB intervention that was even greater with prior exercise (Coen et al., 2015). This 
decrease was associated with improved insulin sensitivity in the skeletal muscle. In addition 
they identified Cer 18:0 as reduced after RYGB and exercise but not after RYGB only (Coen 
et al., 2015). Interestingly, lipidomic analysis showed that in skeletal muscle from mice fed 
with high fat diet for 3 weeks to induce insulin resistance, Cer 18:0 was the only lipid species 
that significantly increased (Turner et al., 2013). Collectively, this draws attention to this 
specific ceramide species that is also altered in the skeletal muscle biopsies of our cohort. 
Further investigation is needed to identify the relevance and relation of specific lipid species in 
the development of insulin resistance.  
Our results show that a relatively short diet intervention in obese insulin resistant subjects has 
a substantial impact on weight loss and insulin levels. This improvement could be a result of 
increased fatty acid uptake in the skeletal muscle and thus clearance of fatty acids from the 
circulation, as well as increased mitochondrial fatty acid oxidation, as indicated by the altered 
gene expression. In addition, the diet intervention induced changes in the lipid profile of 
skeletal muscle, which could have an impact, with four specific lipid species decreasing in an 
inverse correlation with insulin sensitivity. 
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This study pinpoints the importance of studying the specific lipid species to understand the 
influence of lipids upon skeletal muscle metabolism, as there was no change in total lipids 
within each lipid class. Although the main consensus today is that total intra myocellular lipid 
content is not of major importance (Coen & Goodpaster, 2012), it would have been of interest 
to measure the change in our cohort. This was not possible though, taken the limited amount 
of skeletal muscle tissue from the biopsy.  
We only had access to a small cohort (n=8) and the diet intervention only endured for three 
weeks. With a larger cohort and longer intervention we might have seen more dramatic 
changes in lipid profiles. Small alterations in lipid species level could have been masked by 
the individual differences. We rely on insulin levels and HOMA-IR to estimate the change in 
insulin sensitivity. However, the most accurate way to evaluate skeletal muscle insulin 
sensitivity is by euglycaemic clamp, which we did not have the opportunity to perform. 
However, whole-body insulin sensitivity is associated with skeletal muscle insulin action 
(Tripathy, Almgren, Tuomi, & Groop, 2004), suggesting that HOMA-IR can be used as a 
reflection also of peripheral insulin sensitivity.  
Interestingly, the KEGG analysis showed that inflammatory gene pathways were upregulated 
in skeletal muscle after the diet intervention. This is in contrast out hypothesis since obesity 
and insulin resistance are associated with inflammation, and one would have thought that by 
reducing weight and reducing insulin levels, inflammation would decrease. We did not 
measure inflammatory parameters in the blood, but mRNA of IL6 was increased (Figure 16) 
which supports the KEGG analysis data. Other studies of diet- and RYGB interventions that 
efficiently induced weight loss and improved insulin sensitivity, have described decreased C-
reactive protein (CRP) levels but unaltered levels of IL-6 and TNF in adipose tissue and in 
blood respectively (Barres et al., 2013; Fritzen et al., 2015). CRP is produced in the liver, 
which may suggest that improved inflammation of the liver could be of higher importance 
than skeletal muscle and also adipose tissue, for the overall improved inflammation seen after 
weight loss.  
Improvements in insulin sensitivity after a diet intervention was associated with increased 
AMPK activity in adipose tissue (Fritzen et al., 2015). In another study, AMPK activity was 
lower in visceral adipose tissue from obese, insulin resistant individuals than BMI-matched 
obese insulin sensitive individuals (Gauthier et al., 2011). In addition, insulin resistance and 
decreased AMPK activity were associated with increased inflammatory markers and 
infiltration of immune cells in the insulin resistant individuals (Gauthier et al., 2011). Calorie 
restriction induces AMPK skeletal muscle activity in mice (P. Wang et al., 2012). A deletion 
of the AMPKα2 subunit in high fat fed mice, prevented improvements in insulin resistance 
after calorie restriction (P. Wang et al., 2012). Thus, AMPK may be an important target in the 
development of insulin resistance. In the light of this, it would be of interest to investigate the 
AMPK activity also in the skeletal muscle biopsies from our cohort and to link this to mRNA 
and plasma levels of inflammatory markers.  
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5 SUMMARY AND CONCLUSION 
The work of this thesis focuses on the effects of external factors such as weight loss, insulin or 
glucose exposure on DNA methylation and gene regulation in clinical samples obtained from 
insulin resistant and type 2 diabetic subjects. We further assessed the effect of 
pharmacological activation to mimic low energy signals on cytokine expression in healthy 
skeletal muscle and we studied changes in lipidomic and gene expression profile in skeletal 
muscle in response to diet-induced weight loss. In summary, this thesis provides insight to 
how changes in energy homeostasis affects gene regulation and lipid profile in skeletal 
muscle.  
Results from this thesis may have future implications for developing new strategies for 
treatment of obesity. Delineating molecular changes in relevant clinical tissues could pinpoint 
novel regulatory sites and targets for pharmacological interventions. Improvement of insulin 
sensitivity per se may also avoid complication of obesity, such as type 2 diabetes, even in the 
absence of weight reduction.  
The specific conclusions are;  
1. Promoter DNA methylation of metabolic and inflammatory targets, is altered by low 
calorie diet (PGC1α) and RYGB surgery (IL6, IL1β, TNF and PDK4) in peripheral 
blood. The changes in promoter DNA methylation could play a role in whole-body 
metabolic health. However, DNA methylation of these targets in peripheral blood 
appears to be tissue specific and may not be a suitable proxy of DNA methylation 
mark in skeletal muscle.  
 
2. Short insulin and glucose exposure alters the DNA methylation profile in skeletal 
muscle, especially of gene pathways involved in metabolism. DAPK3 DNA 
methylation is different between type 2 diabetic and normal glucose tolerant 
individuals, and is altered by insulin and glucose.  
 
3. The AMPK activator AICAR reduced IL6 and LIF mRNA in skeletal muscle by 
inhibiting transcription, in particilar for IL6 mRNA, likely through interaction with the 
transcription factor Sp1. We identified the transcription factor Zbtb14 as a novel 
regulator of basal LIF mRNA in skeletal muscle.  
 
4. A three-week diet intervention induced weight loss and improved insulin sensitivity. 
The diet-intervention increased expression of genes involved in promoting fatty acid 
oxidation in skeletal muscle. The diet also induced an altered lipid profile with the 
specific lipids PE(36:1), SM(d18:1/20:0), TG(54:0) and TG(56:1) being inversely 
correlated to insulin sensitivity measured by HOMA-IR. 
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Figure 30. Summary of the external factors, affecting skeletal muscle metabolism studied in this thesis.  
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6 FUTURE PERSPECTIVES 
This thesis has focused on several aspects of skeletal muscle metabolism, using different 
techniques such as gene and methylation arrays, lipidomic analysis and in vitro silencing of 
genes using siRNA. All these techniques are constantly improving, providing deeper and more 
refined information, that contributes to new insights and applications in the metabolic field.  
6.1 Epigenetic regulation 
The field of epigenetics is still in its cradle and the understanding of how epigenetic marks 
ultimately regulate our phenotype is still unclear. There is evidence that DNA methylation is 
affected by histone modifications (Baubec et al., 2015) and that small non-coding RNA and 
transcription factors can guide and regulate the enzymes involved in de novo methylation 
(Chan et al., 2004). Simultaneous studies of gene expression, DNA methylation, non-coding 
RNA and histone modifications, particularly with singe cell techniques, will most likely add 
new information to this field. In paper I, we concluded that in our cohort, DNA methylation 
in peripheral blood was not a useful proxy for skeletal muscle DNA methylation. DNA 
methylation is tissue specific but also heterogeneous within a tissue (reviewed in (van Dijk et 
al., 2015) and (Bell, 2017)). Single cell sequencing analysis will be helpful also in 
understanding how genetic and epigenetic regulation lead to tissue phenotype.  
6.2 Gene silencing 
In addition to the siRNA technique used in paper 2 and 3, there are other, new tools to silence 
genes, TALENs and CRISPR-Cas9 systems. These systems enable complete silencing of a 
gene, in contrast to the less efficient silencing techniques of siRNA, and are thus useful tools 
to test gene function in cells and organisms. CRISPR-Cas9 has potential also in future gene 
therapy for disease, however there are still not completely resolved issues concerning off 
target effects.  
6.3 Lipidomic analysis  
With the insight that specific lipid species, their localization and turnover matter more to 
metabolic function that the total amounts of lipids, the implication of lipidomic analysis in 
medicine is clear. Today, total plasma triglycerides, LDL and HDL as well as total cholesterol 
are routinely measured in the clinical setting, as an estimate of metabolic health. Recently, a 
Finnish group performed plasma lipidomics in a large prospective study and identified specific 
lipid species in the plasma that could predict which patients who would develop type 2 
diabetes (Suvitaival et al., 2017). Lipidomic analysis may provide new diagnostic and 
prognostic markers, and thus have useful and important implication for obese patients, to help 
guide and personalise dietary and exercise regimes to prevent insulin resistance and type 2 
diabetes.  
6.4 Personalised medicine 
Obesity and insulin resistance are consequences of numerous different factors affecting 
metabolism. There are currently tools to map the genetic, epigenetic, metabolomic and gut 
microbiotic profiles of an individual. Thus, with the possibility of deep and personalised 
information, future challenges lie not only in deconvoluting the data, to predict future risk and 
personalized intervention, but also in determining the cost/benefit of the different possible 
analysis.  
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7 SVENSK POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
Fler människor på jorden är i dag överviktiga än underviktiga. Typ 2-diabetes, hjärt- och 
kärlsjukdomar, och flera typer av cancer är starkt förknippade med fetma. Lågkaloridiet 
kombinerad med beteendeterapi kan visserligen leda till viktnedgång men den enda riktigt 
effektiva och långsiktiga behandlingen för fetma är i dag kirurgi. Fetmaepidemin kan till viss 
del förklaras av samspelet mellan gener och miljö, där våra gener har selekterats för att öka vår 
överlevnad under perioder av svält. Forskning har visat att miljöfaktorer även kan påverka 
våra gener genom att olika epigenetiska markörer.  
Skelettmuskeln är det organ i kroppen som omsätter störst mängd näringsämnen. Vid övervikt 
och fetma har kroppen ett överskott på kolhydrater och fetter som ska lagras och omsättas 
framför allt i skelettmuskeln. Om skelettmusklerna får för mycket näringsämnen som de inte 
kan omsätta, leder detta till stress i de system i skelettmuskelcellerna som hanterar 
ämnesomsättning och lagring. Denna stress, samt förekomsten av överskott på näringsämnen i 
sig, leder till inflammation. Inflammationen försämrar i sin tur cellernas förmåga att hantera 
näringsämnen, vilket leder till en ond spiral.  
Epigenetik betyder ”ovanpå” (från grekiskan epi) generna och är ett sätt att reglera hur våra 
gener uttrycks. Epigenetik omfattar bland annat DNA-metylering, den mekanism som 
studerats i denna avhandling. Genom metylering sätts ”små flaggor” på DNA-sekvensen vilket 
förändrar dess förmåga till uttryck, det vill säga om genen så småningom blir översatt till 
protein. Olika faktorer, från miljögifter, till vad vi äter och hur vi tränar, påverkar vilka gener 
som uttrycks och blir till protein i kroppen. Detta påverkar sedan risken att drabbas av olika 
sjukdomar. 
Det övergripande målet med denna avhandling är att studera hur externa faktorer så som 
rubbningar i energibalansen, insulin eller glukos, påverkar genuttryck. Syftet är att förstå de 
mekanismer som leder till försämrad förmåga att hantera näringsämnen i skelettmuskeln. 
Insulin är ett centralt hormon som styr ämnesomsättningen. En oförmåga hos skelettmuskeln 
att ta hand om, och omsätta en ökad mängd kolhydrater och fetter är starkt kopplat till en 
minskad känslighet för insulin i skelettmuskeln, vilket är förstadiet till typ 2 diabetes. Fetma är 
ett tillstånd starkt förknippat med minskad insulinkänslighet i skelettmuskeln, och utgör därför 
en viktig modell för våra studier i denna avhandling.  
I studie 1 undersökte vi blod från feta försökspersoner före och efter en lågkaloridiet och 
sedan även 12 månader efter fetmakirurgi. Försökspersonerna gick i genomsnitt ner 5 kg i vikt 
efter 14 dagars diet och sedan ytterligare 38 kg efter fetmakirurgin. Försökspersonernas 
blodsocker, insulin- och blodfettsnivåer förbättrades något efter dieten men mer väsentliga 
förbättringar sågs efter kirurgin. Vi studerade hur DNA metylering i blodet av utvalda gener 
förändrades av dieten och kirurgin. Resultaten visar att DNA metyleringen i blodet av gener, 
som vi tror påverkar vår ämnesomsättning och graden av inflammation, var mer förändrade 
efter kirurgin än efter dieten. 
I studie 2 undersökte vi hur en timmes insulinexponering påverkade DNA metyleringen av 
våra gener i skelettmuskelbiopsier. Trots kort insulinexponering, fann vi ändrad DNA 
metylering av flera genfamiljer involverade i ämnesomsättning och inflammation. Vi 
identifierade en gen, DAPK3, vars DNA metylering hade förändrats, som inte tidigare 
identifierats som betydelsefull inom ämnesomsättningen. Graden av DNA metylering av 
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DAPK3 skilde sig inte bara efter insulinexponering, utan även i skelettmuskeln mellan typ 2 
diabetiker och friska, och förändrades ytterligare av en glukosbelastning. Sammanfattningsvis 
kan en kort exponering för insulin eller glukos påverka DNA metyleringen av gener. 
I studie 3 stimulerade vi skelettmuskelbiopsier istället med en AMP-analog, som signalerar 
till cellen att energi-nivån är låg. Uttryck av gener involverade i inflammation reducerades 
efter exponeringen. En tolkning av resultaten är att skelettmuskeln vill minska graden av 
inflammation för att spara energi, eftersom inflammationsprocesser förbrukar energi. Vi fann 
två, inom området ämnesomsättning, ej tidigare beskrivna transkriptionsfaktorer, Sp1 och 
Zbtb14, som var involverade i regleringen av inflammationsgenerna IL6 och LIF. 
I studie 4 undersökte vi skelettmuskelbiopsier från feta försökspersoner före och efter en tre 
veckor lågkaloridiet. Försökspersonerna gick i genomsnitt ner 8 kg i vikt och förbättrade sina 
blodvärden. Vi såg att genfamiljer involverade i fettförbränning och inflammation ändrade sitt 
uttryck efter dieten. Vi bekräftade att specifika gener viktiga för fettomsättningen ökade i 
uttryck. Vi undersökte sedan hur fettsammansättningen förändrades i muskeln, och såg att 
specifika fettyper minskade väsentligt efter dieten. Dessa specifika fettyper var korrelerade 
med förändring i muskelns insulinkänslighet. Sammanfattningsvis kan dessa fynd ha en 
betydelse för den förbättrade ämnesomsättningen i skelettmuskeln efter viktnedgång. 
Sammanfattningsvis har vi studerat blod och skelettmuskel före och efter viktnedgång, hos 
feta och normalviktiga, med eller utan nedsatt insulinkänslighet eller typ 2 diabetes. Vi har 
undersökt vilka mekanismer som kan ligga till grund för den förbättrade insulinkänsligheten 
efter viktnedgång. Gener, viktiga för ämnesomsättningen i bland annat skelettmuskeln, är 
förändrat metylerade i blodet efter fetmakirurgi. Vi ser även att gener som ger en ökad 
fettförbränning i skelettmuskeln ökar, specifika fettyper minskar, samtidigt som insulinvärdet i 
blodet sjunker vid viktnedgång efter lågkaloridiet. Resultaten i denna avhandling ger ökad 
insikt i hur förändringar i energibalansen kan påverka genuttryck och lipidsammansättning i 
skelettmuskeln, vilket i sin ur är förknippat med förändringar i insulinkänslighet.  
Det krävs vidare studier för att utreda vilka faktorer som är avgörande för att förbättra insulin 
känsligheten i skelettmuskeln. Ökad kunskap är avgörande för att kunna erbjuda bättre 
behandlingsrekommendationer och behandling och därmed bromsa den pågående epidemin av 
fetmainducerad insulinresistens. 
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